<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004890.pub2" GROUP_ID="LIVER" ID="924603091310114055" MERGED_FROM="" MODIFIED="2008-10-16 19:12:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;/p&gt;&lt;p&gt;Old title: Endoscopic balloon sphincter dilation (sphincteroplasty) versus sphincterotomy for common bile duct stones&lt;br&gt;Old title: Endoscopic Balloon Sphincter Dilation (Sphincteroplasty) vs. Sphincterotomy for Common Bile Duct Stones&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 18:06:27 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" REVIEW_NO="01" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2008-10-16 19:12:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE>Endoscopic balloon sphincter dilation (sphincteroplasty) versus sphincterotomy for common bile duct stones</TITLE>
<CONTACT>
<PERSON ID="95D672EB82E26AA201C330AAED819437" MODIFIED="2008-10-16 17:57:15 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Benjamin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Weinberg</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1>benjaminweinberg@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION/>
<ADDRESS_1>932 N Curson Ave Apt #3</ADDRESS_1>
<ADDRESS_2/>
<CITY>West Hollywood</CITY>
<ZIP>CA 90046</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 323 850 1459</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-10-16 18:06:27 +0100" MODIFIED_BY="dimitrinka nikolova">
<PERSON ID="95D672EB82E26AA201C330AAED819437" MODIFIED="2008-10-16 17:57:07 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Benjamin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Weinberg</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1>benjaminweinberg@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION/>
<ADDRESS_1>932 N Curson Ave Apt #3</ADDRESS_1>
<ADDRESS_2/>
<CITY>West Hollywood</CITY>
<ZIP>CA 90046</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 323 850 1459</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="168FEC0282E26AA200D5E26B8B81B519" MODIFIED="2008-10-16 18:06:27 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Waleed</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shindy</LAST_NAME>
<SUFFIX/>
<POSITION>Gastroenterologist</POSITION>
<EMAIL_1>wshindy@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Gastroenterology</DEPARTMENT>
<ORGANISATION/>
<ADDRESS_1>Olive View-UCLA Medical Center</ADDRESS_1>
<ADDRESS_2>14445 Olive View Dr., 2B-182</ADDRESS_2>
<CITY>Sylmar</CITY>
<ZIP/>
<REGION>CA</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>818 364 3205</PHONE_1>
<PHONE_2/>
<FAX_1>818 364 4573</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6033D5DC82E26AA2004333592187822E" MODIFIED="2008-10-16 18:04:54 +0100" MODIFIED_BY="dimitrinka nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Simon</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lo</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>simon.lo@cshs.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION/>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>West Hollywood</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 310 423 6082</PHONE_1>
<PHONE_2>+1 888 344 3378</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-10-16 19:12:29 +0200" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Minor update: 05/09/06&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 15/01/04&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:57:38 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova">
<UP_TO_DATE>
<DATE DAY="22" MONTH="8" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="1" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="19" MONTH="8" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="16" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-16 17:57:25 +0100" MODIFIED_BY="dimitrinka nikolova"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>UCLA - San Fernando Valley Program</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-16 18:00:06 +0100" MODIFIED_BY="dimitrinka nikolova">
<SUMMARY>
<TITLE>Endoscopic balloon dilation seems inferior to endoscopic sphincterotomy for common bile duct stone removal</TITLE>
<SUMMARY_BODY>
<P>Endoscopic balloon dilation is slightly less successful than endoscopic sphincterotomy in stone extraction and more risky in inducing pancreatitis. However, endoscopic balloon dilation seems to have a clinical role in patients who have a coagulopathy, who are at risk for infection, and possibly in those who are older.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Endoscopic balloon dilation was introduced as an alternative to endoscopic sphincterotomy to preserve the sphincter of Oddi and avoid undesirable effects due to an incompetent sphincter. Endoscopic balloon dilation has been largely abandoned by USA endoscopists due to increased risks of pancreatitis noted in one multicentre trial, but is still practiced in parts of Asia and Europe. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the beneficial and harmful effects of endoscopic balloon dilation versus endoscopic sphincterotomy in the management of common bile duct stones. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I>, the<I> Cochrane Central Register of Controlled Trials </I>(<I>CENTRAL</I>) in <I>The Cochrane Library</I>, <I>MEDLINE</I>, and <I>EMBASE </I>until January 2004<I>. </I>We hand searched <I>Gastrointestinal Endoscopy</I> (1983 to 2002), read through bibliographies of all included randomised clinical trials, and contacted all primary authors regarding missed randomised trials. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised clinical trials comparing endoscopic balloon dilation versus endoscopic sphincterotomy in removal of common bile duct stones irrespective of publication status, language, or blinding.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data collection was done by two independent authors for decisions on study inclusion, data abstraction, and quality assessment. When there was a non-resolvable discrepancy, the third author made the final decision. Analysis was run with RevMan Analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Fifteen randomised trials met our inclusion criteria (1768 participants). Less than half of the trials reported adequate methods of randomisation and only two trials used blinded outcome assessment. Endoscopic balloon dilation is statistically less successful for stone removal (relative risk (RR) 0.90, 95% confidence interval (CI) 0.84 to 0.97, random-effects), requires higher rates of mechanical lithotripsy (RR 1.34, 95% CI 1.08 to 1.66, random-effects), and carries a higher risk of pancreatitis (RR 1.98, 95 CI 1.35 to 2.90, fixed-effect). Conversely, endoscopic balloon dilation has statistically significant lower rates of bleeding. Endoscopic balloon dilation leads to significantly less short-term infection and long-term infection. There was no statistically significant difference with regards to mortality, perforation, or total short-term complications between endoscopic balloon dilation and endoscopic sphincterotomy. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Endoscopic balloon dilation is slightly less successful than endoscopic sphincterotomy in stone extraction and more risky regarding pancreatitis. However, endoscopic balloon dilation seems to have a clinical role in patients who have coagulopathy, who are at risk for infection, and possibly in those who are older.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-16 18:00:06 +0100" MODIFIED_BY="dimitrinka nikolova">
<BACKGROUND>
<P>Endoscopic sphincterotomy was originally introduced more than 30 years ago for elderly and frail patients unfit for surgery (<LINK REF="REF-Classen-1974" TYPE="REFERENCE">Classen 1974</LINK>). Over the last two decades endoscopic sphincterotomy has become the treatment of choice for stone extraction in a growing population of significantly younger and healthier patients. Despite its relative safety, endoscopic sphincterotomy is the most dangerous procedure performed by endoscopists with overall complication rates occurring in about 10% (<LINK REF="REF-Cotton-1991" TYPE="REFERENCE">Cotton 1991</LINK>; <LINK REF="REF-Freeman-1996" TYPE="REFERENCE">Freeman 1996</LINK>). As a result, the short-term risks of pancreatitis, bleeding, perforation, and death, along with the potential long-term complications of papillary stenosis and the danger of bacterial contamination of biliary system are important concerns (<LINK REF="REF-Bergman-1996" TYPE="REFERENCE">Bergman 1996</LINK>).</P>
<P>Endoscopic balloon dilation was first proposed in 1983 by Staritz et al (<LINK REF="REF-Staritz-1983" TYPE="REFERENCE">Staritz 1983</LINK>) as an alternative to endoscopic sphincterotomy with the hope of avoiding these short-term and long-term complications through preserving the sphincter of Oddi. As a therapeutic maneuver, endoscopic balloon dilation has been shown to be successful with ductal stone clearance rates of 80% to 100% in several case series (<LINK REF="REF-Groen-1989" TYPE="REFERENCE">Groen 1989</LINK>; <LINK REF="REF-May-1993" TYPE="REFERENCE">May 1993</LINK>; <LINK REF="REF-MacMathuna-1994" TYPE="REFERENCE">MacMathuna 1994</LINK>; <LINK REF="REF-MacMathuna-1995" TYPE="REFERENCE">MacMathuna 1995</LINK>; <LINK REF="STD-Bergman-1997b" TYPE="STUDY">Bergman 1997b</LINK>; <LINK REF="STD-Komatsu-1998a" TYPE="STUDY">Komatsu 1998a</LINK>). However, many gastroenterologists are hesitant to accept endoscopic balloon dilation as an alternative to endoscopic sphincterotomy primarily for fears of an increased risk of pancreatitis.</P>
<P>Rates of pancreatitis in case series evaluating endoscopic balloon dilation for common bile duct stone removal range from 0% to 7% (<LINK REF="REF-Staritz-1983" TYPE="REFERENCE">Staritz 1983</LINK>; <LINK REF="REF-Cotton-1991" TYPE="REFERENCE">Cotton 1991</LINK>; <LINK REF="REF-May-1993" TYPE="REFERENCE">May 1993</LINK>; <LINK REF="REF-MacMathuna-1995" TYPE="REFERENCE">MacMathuna 1995</LINK>; <LINK REF="REF-Gottlieb-1998" TYPE="REFERENCE">Gottlieb 1998</LINK>; <LINK REF="STD-Komatsu-1998a" TYPE="STUDY">Komatsu 1998a</LINK>) compared with reported rates of 0% to 39% in series evaluating endoscopic sphincterotomy for stone removal (<LINK REF="REF-Cotton-1991" TYPE="REFERENCE">Cotton 1991</LINK>; <LINK REF="REF-Freeman-1996" TYPE="REFERENCE">Freeman 1996</LINK>). While randomised clinical trials from Europe and Asia have demonstrated similar rates of pancreatitis between the endoscopic balloon dilation and endoscopic sphincterotomy groups (<LINK REF="STD-Minami-1995" TYPE="STUDY">Minami 1995</LINK>; <LINK REF="STD-Bergman-1997a" TYPE="STUDY">Bergman 1997a</LINK>; <LINK REF="STD-Cho-1998" TYPE="STUDY">Cho 1998</LINK>; <LINK REF="STD-Ochi-1999" TYPE="STUDY">Ochi 1999</LINK>), one international multicenter trial noted a higher incidence of pancreatitis with two subsequent deaths in the endoscopic balloon dilation group (<LINK REF="REF-DiSario-1997" TYPE="REFERENCE">DiSario 1997</LINK>; <LINK REF="REF-DiSario-1999" TYPE="REFERENCE">DiSario 1999</LINK>). Although endoscopic balloon dilation is a popular alternative used for stone extraction in parts of Europe, Japan, and Korea (<LINK REF="REF-Sheth-2001" TYPE="REFERENCE">Sheth 2001</LINK>), the majority of endoscopists in the US have abandoned its routine use mainly for fears of pancreatitis.</P>
<P>On the other hand endoscopic balloon dilation appears to have lower rates of bleeding and perforation. While endoscopic sphincterotomy involves cutting and carries bleeding rates of 2% to 5% (<LINK REF="REF-Cotton-1991" TYPE="REFERENCE">Cotton 1991</LINK>; <LINK REF="REF-Freeman-1996" TYPE="REFERENCE">Freeman 1996</LINK>), endoscopic balloon dilation theoretically preserves the biliary sphincter with reportedly no bleeding (<LINK REF="REF-Staritz-1983" TYPE="REFERENCE">Staritz 1983</LINK>; <LINK REF="REF-Cotton-1991" TYPE="REFERENCE">Cotton 1991</LINK>; <LINK REF="REF-MacMathuna-1995" TYPE="REFERENCE">MacMathuna 1995</LINK>; <LINK REF="STD-Minami-1995" TYPE="STUDY">Minami 1995</LINK>; <LINK REF="REF-Freeman-1996" TYPE="REFERENCE">Freeman 1996</LINK>; <LINK REF="STD-Bergman-1997a" TYPE="STUDY">Bergman 1997a</LINK>; <LINK REF="REF-DiSario-1997" TYPE="REFERENCE">DiSario 1997</LINK>; <LINK REF="STD-Komatsu-1998a" TYPE="STUDY">Komatsu 1998a</LINK>; <LINK REF="REF-DiSario-1999" TYPE="REFERENCE">DiSario 1999</LINK>). Consequently, endoscopic balloon dilation has been shown to be safe even in patients with coagulopathies who normally carry a 6.6% to 14.3% mortality rate with endoscopic sphincterotomy (<LINK REF="REF-Moreira-1991" TYPE="REFERENCE">Moreira 1991</LINK>; <LINK REF="REF-Sugiyama-1993" TYPE="REFERENCE">Sugiyama 1993</LINK>; <LINK REF="REF-Freeman-1996" TYPE="REFERENCE">Freeman 1996</LINK>; <LINK REF="STD-Kawabe-1996a" TYPE="STUDY">Kawabe 1996a</LINK>; <LINK REF="STD-Komatsu-1998a" TYPE="STUDY">Komatsu 1998a</LINK>). The risk of perforation also appears to be lower in endoscopic balloon dilation groups with reported rates in case series of 0% to 1% as compared with 1% to 2% in endoscopic sphincterotomy series (<LINK REF="REF-Cotton-1991" TYPE="REFERENCE">Cotton 1991</LINK>; <LINK REF="REF-May-1993" TYPE="REFERENCE">May 1993</LINK>; <LINK REF="REF-MacMathuna-1995" TYPE="REFERENCE">MacMathuna 1995</LINK>; <LINK REF="REF-Freeman-1996" TYPE="REFERENCE">Freeman 1996</LINK>; <LINK REF="STD-Komatsu-1998a" TYPE="STUDY">Komatsu 1998a</LINK>).</P>
<P>Because endoscopic balloon dilation is felt to have a lower incidence of bleeding, it is generally advocated as a safer alternative to endoscopic sphincterotomy in patients with atypical anatomy such as those with duodenal diverticulum or past Roux-en-Y or Billroth II operation. To date at least two trials involving patients with a history of a Billroth II procedure reported no complications of bleeding (<LINK REF="STD-Kalinsky-1999a" TYPE="STUDY">Kalinsky 1999a</LINK>; <LINK REF="REF-Bergman-2001b" TYPE="REFERENCE">Bergman 2001b</LINK>).</P>
<P>Since endoscopic balloon dilation has been demonstrated to preserve the sphincter of Oddi, the potential long-term consequences of endoscopic sphincterotomy are theoretically avoided (<LINK REF="STD-Minami-1995" TYPE="STUDY">Minami 1995</LINK>). In retrospective studies reviewing patients 11 to 20 years after endoscopic sphincterotomy the noted long-term complications include papillary stenosis, loss of sphincter of Oddi function, and bacterial contamination of the normally sterile biliary tree (<LINK REF="REF-Gregg-1985" TYPE="REFERENCE">Gregg 1985</LINK>; <LINK REF="REF-Skar-1986" TYPE="REFERENCE">Skar 1986</LINK>; <LINK REF="REF-Hawes-1990" TYPE="REFERENCE">Hawes 1990</LINK>; <LINK REF="REF-Sand-1992" TYPE="REFERENCE">Sand 1992</LINK>; <LINK REF="REF-Heinerman-1994" TYPE="REFERENCE">Heinerman 1994</LINK>; <LINK REF="REF-Sugiyama-1998" TYPE="REFERENCE">Sugiyama 1998</LINK>; <LINK REF="REF-Tanaka-1998" TYPE="REFERENCE">Tanaka 1998</LINK>; <LINK REF="REF-Sheth-2001" TYPE="REFERENCE">Sheth 2001</LINK>; <LINK REF="REF-Sugiyama-2002" TYPE="REFERENCE">Sugiyama 2002</LINK>). This bacterial contamination may lead to recurrence of bile duct stones as a result of deconjugation of bilirubin by bacterial enzymes, inflammatory changes of the biliary system, recurrent ascending cholangitis, and a theorized potentially malignant degeneration (<LINK REF="REF-Goldman-1983" TYPE="REFERENCE">Goldman 1983</LINK>; <LINK REF="REF-Greenfield-1985" TYPE="REFERENCE">Greenfield 1985</LINK>; <LINK REF="REF-Kurumado-1994" TYPE="REFERENCE">Kurumado 1994</LINK>; <LINK REF="REF-Maki-1966" TYPE="REFERENCE">Maki 1966</LINK>).</P>
<P>At the time this systematic review was started we were unable to identify meta-analyses or systematic reviews on sphincteroplasty versus sphincterotomy for patients with common bile duct status. However, during the completion of this review a meta-analysis was published in 2004 (<LINK REF="REF-Baron-2004" TYPE="REFERENCE">Baron 2004</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To compare endoscopic balloon dilation (EBD) with endoscopic sphincterotomy (ES) in the management of common bile duct stones with regards to success with stone removal, short-term complications (bleeding, perforation, and pancreatitis) and long-term complications (strictures, recurrent stones, cholangitis, and cancer).</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-16 18:00:06 +0100" MODIFIED_BY="dimitrinka nikolova">
<SELECTION_CRITERIA MODIFIED="2008-10-16 18:00:06 +0100" MODIFIED_BY="dimitrinka nikolova">
<CRIT_STUDIES>
<P>Randomised clinical trials comparing endoscopic balloon dilation versus endoscopic sphincterotomy in removal of common bile duct stones. We included trials irrespective of publication status (unpublished or published as an article, abstract, or a letter), language (no language limitations were applied), or blinding. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with common bile duct stones noted on endoscopic retrograde cholangiopancreatography. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Endoscopic balloon dilation compared with endoscopic sphincterotomy with or without the aid of balloon extraction, basket extraction, mechanical lithotripsy, or endoscopic sonic lithotripsy for stone extraction.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-16 18:00:06 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>
<B>
<I>Primary outcome measures</I>
</B>
<U>
<BR/>
</U>(1) Technical success divided into:<BR/>(1a) Ability to remove stone(s) with first attempt.<BR/>(1b) No evidence of stone recurrence in more than six months.</P>
<P>
<B>
<I>Primary adverse event outcomes</I>
</B>
<BR/>(2) Mortality:<BR/>(2a) Mortality within first 30 days of procedure.<BR/>(2b) Mortality at maximal follow-up.<BR/>(3) Pancreatitis as defined by each trial.<BR/>(4) Bleeding as defined by each trial.<BR/>(5) Perforation as defined by each trial.<BR/>(6) Infection divided into:<BR/>(6a) Biliary tract infection. Evidence of fever or septicemia, leukocytosis, related to the biliary tract.<BR/>(6b) Non-biliary tract infection. Evidence of fever or septicemia, leukocytosis, unrelated to the biliary tract.<BR/>(7) Total combined primary adverse events.</P>
<P>
<B>
<I>Secondary adverse event outcomes</I>
</B>
<BR/>(8) Transient sphincter obstruction: Defined as post procedure rise in liver transaminases with or without associated symptoms or known liver damage.<BR/>(9) Miscellaneous:<BR/>(9a) Pneumonia.<BR/>(9b) Adverse reaction to interventions.<BR/>(9c) Others as defined by each trial.<BR/>(10) Total of secondary adverse events.<BR/>(11) Total overall (primary and secondary) adverse events.</P>
<P>
<B>
<I>Other secondary outcomes</I>
</B>
<BR/>(12) Long-term complications (greater than 30 days):<BR/>(12a) Papillary stenosis.<BR/>(12b) Recurrent ascending cholangitis.<BR/>(12c) Bile duct malignancy.<BR/>(12d) Others as defined by each trial.<BR/>(13) Cost as measured in US dollars.</P>
<P>
<B>Methodological quality</B>
<BR/>In addition to data abstracted from the trial manuscripts (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), we recorded measures of trial quality. Due to the risk of overestimation of intervention effects in randomised trials with inadequate components (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>), we assessed the methodological quality by the four separate components, described below.</P>
<P>
<B>
<I>Generation of the allocation sequence</I>
</B>
<BR/>The procedure used to create a random sequence ensuring that each participant has a known, unpredictable, and usually equal chance of being assigned to intervention groups. The allocation sequence generation can be classified as:<BR/>
</P>
<UL>
<LI>Adequate, if the allocation sequence was generated by a computer or random number table. Drawing of lots, tossing of a coin, shuffling of cards, or throwing dice may also be considered as adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure;</LI>
<LI>Unclear, if the trial was described as randomised, but the method used for the allocation sequence generation was not described;</LI>
<LI>Inadequate, if a system involving dates, names, or admittance numbers were used for the allocation of patients. Such studies are known as quasi-randomised studies and should usually be excluded from systematic reviews because they are associated with a considerable risk of bias.</LI>
</UL>
<P>
<B>
<I>Allocation concealment</I>
</B>
<BR/>The procedure used to conceal the allocation sequence from the investigators who assign participants to the intervention groups. The allocation concealment can be classified as:<BR/>
</P>
<UL>
<LI>Adequate, if the allocation of patients involved a central independent unit, on-site locked computer, identically appearing sealed envelopes. Envelopes should be serially numbered, sealed, and opaque. However, this information is rarely provided, indicating an increased risk of bias. In that case, sealed envelopes may constitute an intermediate category between adequate and unclear;</LI>
<LI>Unclear, if the trial was described as randomised, but the method used to conceal the allocation was not described;</LI>
<LI>Inadequate, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised.</LI>
</UL>
<P>
<B>
<I>Blinding (or masking)</I>
</B>
<BR/>The procedure used to keep trial participants, health care providers, and outcome assessors unaware of the intervention to which participants were assigned. Judicial assessors of outcomes, data analysts, data safety, monitoring committee members, and manuscript writers can also be blinded. In some cases, evaluation of whether outcome assessors were blinded may be sufficient. This primarily concerns trials on surgery or other procedures. Blinding can then be classified as:<BR/>
</P>
<UL>
<LI>Adequate, if the trial was described as double blind and the method of blinding involved blinding of outcome assessors;</LI>
<LI>Unclear, if the trial was described as double blind, but the method of blinding was not described;</LI>
<LI>Not performed, if the trial was not double blind.</LI>
</UL>
<P>
<B>
<I>Follow-up</I>
</B>
<BR/>The purpose of randomization is to generate comparable intervention groups. This baseline equivalence may be disrupted if participants are lost to follow up. To evaluate the risk of such attrition bias, we suggest that authors extract the number and reasons for dropouts and withdrawals. Extraction of this information can be difficult due to unclear reporting. It may therefore sometimes be relevant to extract the adequacy of follow-up reports. The reported follow-up can be classified as:<BR/>
</P>
<UL>
<LI>Adequate, if the numbers and reasons for dropouts and withdrawals in all intervention groups were described or if it was specified that there were no dropouts or withdrawals;</LI>
<LI>Unclear, if the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated;</LI>
<LI>Inadequate, if the number or reasons for dropouts and withdrawals were not described.</LI>
</UL>
<P>When trials did not clearly state that intention-to-treat analysis was used, attempts were made to collect data in an intention-to-treat manner from examination of the manuscript. If the data could not be clearly adjusted in this fashion, then the data were used as they were. In the best-case scenario all authors would have provided clarification of all missing data and whether or not intention-to-treat methodologies were used. In a worst-case scenario, when the use of intention-to-treat methodologies were not clear, the data abstractors had to make attempts to conform the data in such a way as to account for patient dropouts or missing data.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-16 17:59:41 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I>, the <I>Cochrane Central Register of Controlled Trials </I>(<I>CENTRAL</I>) in <I>The Cochrane Library, MEDLINE, </I>and<I> EMBASE </I>until January 2004<I>. </I>The search strategies used with the time span of the searches are given in Additional Table 1. We conducted hand searches in abstracts from meetings held from 1983 to the present by American Society for Gastrointestinal Endoscopy (ASGE). Bibliographies of all included trials were searched for references not found by our searches. Then attempts were made to locate abstracts and if necessary the full texts of all titles which appeared relevant. Attempts were made to contact all primary authors of included trials. They were sent a list of included trials, and asked about other randomised clinical trials that we may have missed.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-16 17:59:45 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>All trials found during our search were first assessed by review of the abstract or, if no abstract is available or review of the abstract was insufficient, a decision was made after review of the full text of the article. All identified trials were reviewed in a non-blinded fashion by two independent authors (BW and WS) to decide whether trials should have been included or excluded. If there was disagreement between authors, then the third author (SL) reviewed the trial and made the final decision as to inclusion or exclusion. If full articles were not available, abstracts were used if there was sufficient information. If there was inadequate information, then the primary author was contacted in an attempt to obtain necessary information. In cases of duplicate publications, all versions were reviewed.</P>
<P>Excluded trials were listed and reasons for exclusion were noted.</P>
<P>
<B>Data extraction</B>
<BR/>Data abstraction was recorded on the data abstraction form (see Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) by two independent authors (BW) and (WS). If differences of opinion could not be resolved between the two authors, than the third author (SL) made the final decision.</P>
<P>
<B>Statistical assessment</B>
<BR/>The software package (RevMan Analyses) provided by The Cochrane Collaboration was used for all analyses (<LINK REF="REF-RevMan-2003" TYPE="REFERENCE">RevMan 2003</LINK>).</P>
<P>Although the individual adverse events were analysed, as expected due to low adverse event rates and trials of small to moderate size, most attention was focused on analysis of the following five outcome variables: treatment failure, pancreatitis, total primary adverse events, and total adverse events.</P>
<P>The two treatment modalities were compared within each trial using the relative risk (RR) with 95% confidence intervals (CI). For continuous variables the weighted mean difference (WMD) between groups with 95% CI was used. Using each trial as a stratum, RRs were tested for homogeneity using a chi-squared test. A P-value of less than 0.10 was used as an indicator of significant heterogeneity; I<SUP>2</SUP> indices were reported to assist in evaluating the degree of heterogeneity. We analysed data by both a fixed-effect and a random-effects model analyses. If both fixed-effect and random-effects analyses were significant only one was reported. Random-effects analysis was reported if both analyses demonstrated a significant difference as it gives wider confidence intervals and fixed-effect analysis was reported if both analyses were nonsignificant as it gives tighter confidence intervals.</P>
<P>Regardless of heterogeneity, the following sub-groups of study variables were examined:</P>
<P>(Note: Since individual patient data were not used for our analysis, means values were used for continuous variables. Also, in our attempt to dichotomize each trial for subgroup analysis majorities were used when appropriate to define each trial.)</P>
<UL>
<LI>Trial quality</LI>
</UL>
<P>- Adequate generation of the allocation sequence versus unclear/no generation of the allocation sequence.<BR/>- Adequate allocation concealment versus unclear/no allocation concealment.<BR/>- Adequate blinding versus unclear/no blinding.<BR/>- Adequate intention-to-treat analysis versus unclear/no intention-to-treat analysis.<BR/>
</P>
<UL>
<LI>Size of biliary tract stones</LI>
</UL>
<P>- Smaller than 10 mm versus bigger than or equal to 10 mm.<BR/>
</P>
<UL>
<LI>Number of biliary tract stones</LI>
</UL>
<P>- One stone or more than one stone.<BR/>
</P>
<UL>
<LI>Stone removal characteristics</LI>
</UL>
<P>- Diameter of balloon dilation (less than or equal to 8 mm or larger than 8 mm).<BR/>- Length of time of balloon dilation (less than 45 sec, more than or equal to 45 sec to less than 60 sec, or more than or equal to 60 sec).<BR/>
</P>
<UL>
<LI>Use of somatostatin, octreotide, corticosteroids, gabexate, platelet activating agents, or other prokinase inhibiting agents for prevention of endoscopic retrograde cholangiopancreatography related pancreatitis versus no use.</LI>
<LI>Pancreatic duct stenting prior to sphincteroplasty or sphincterotomy versus no use.</LI>
<LI>Anatomy</LI>
</UL>
<P>- Surgical alteration: Billroth II, or Roux-En-Y, or hepaticojejunostomy, or normal anatomy.<BR/>
</P>
<UL>
<LI>Pre-existing coagulopathy versus normal coagulation.</LI>
<LI>Pure versus blended cut currents during sphincterotomy.</LI>
<LI>Study location (categorized by country/continent).</LI>
</UL>
<P>
<BR/>We had originally planned to examine each point of interest with scatterplots (with each trial as a data point) and to display the trial RR (y-variable) in relation to variables, which might lead to heterogeneity. These variables would have included demographic variables, trial size, and trial quality. It was hypothesized that by dividing the trials into two or three sub-groups, based on study variables, might produce reasonably other further homogeneous trial clusters which would then have been analysed in subgroups. However, these scatterplots were not carried out due to cost and time constraints.</P>
<P>A funnel plot was used on those trials included in the meta-analysis to assess the potential for bias.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Our initial searches identified 50 potential publications. After reading the titles and abstracts, 33 were excluded because they were either duplicates, had no endoscopic sphincterotomy group, or were non-clinical trials. One randomised trial was later excluded after contact with the primary author revealed that it was a quasi-randomised study and another was composed of the same subset of patients from an earlier study. The reasons for exclusion are listed in the table 'Characteristics of excluded studies'. </P>
<P>The remaining 15 publications were randomised clinical trials that reported the random allocation of patients with common bile duct stones to endoscopic balloon dilation versus endoscopic sphincterotomy, thus fulfilling our inclusion criteria. These trials are listed in the table 'Characteristics of included studies'. Fourteen of these randomised trials were published in English and one was published in Korean (<LINK REF="STD-Cho-1998" TYPE="STUDY">Cho 1998</LINK>). Two trials were published only in abstract form (<LINK REF="STD-Chen-1998" TYPE="STUDY">Chen 1998</LINK>; <LINK REF="STD-Iwata-1998" TYPE="STUDY">Iwata 1998</LINK>). Seven trials were from Japan, two from the Netherlands, one from China, one from Korea, one from the UK, one from Germany, one from the US, and one was from a US-international collaboration.</P>
<P>We wrote to the primary authors of all included trials and received responses for only two authors. Both responses were from Dr. Jacques Bergman who clarified missing data for the two trials, which he had authored. </P>
<P>A total of 1768 patients were randomised with the smallest trial consisting of 34 participants and the largest consisting of 282. In total 878 were in the EBD group and 890 were in the ES group. The mean age of patients in the EBD groups ranged from 49 to 75 and in the ES groups from 47 to 71. The mean stone size extracted in the EBD groups ranged from 7 mm to 15.6 mm and in ES groups from 7.3 mm to 16.9 mm. The mean number of stones in the EBD groups ranged from 1.6 to 3.3 and in the ES groups from 1.0 to 3.5. The majority of patients in all the trials consisted of patients with normal anatomy except one trial (<LINK REF="STD-Bergman-2001a" TYPE="STUDY">Bergman 2001a</LINK>), which only assessed patients with a history of a Billroth II procedure. Eleven of the 15 trials used 8 mm diameter balloon dilators in the EBD group, while one used 6 mm to 10 mm balloons (<LINK REF="STD-Iwata-1998" TYPE="STUDY">Iwata 1998</LINK>), one used 8 mm to 12 mm balloons (<LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>), one used 10 mm balloons (<LINK REF="STD-Vlavianos-2003" TYPE="STUDY">Vlavianos 2003</LINK>), and one was unclear as to what size balloons were used (<LINK REF="STD-Chen-1998" TYPE="STUDY">Chen 1998</LINK>).</P>
<P>Thirteen trials examined treatment success and short-term complications in their primary outcomes. One trial (<LINK REF="STD-Yasuda-2001" TYPE="STUDY">Yasuda 2001</LINK>) looked at long-term manometric function and incidence of pneumobilia as its primary outcome, with treatment success and short-term complications being secondary measures. Another trial (<LINK REF="STD-Iwata-1998" TYPE="STUDY">Iwata 1998</LINK>) only published results regarding rates of mechanical lithotripsy and complications. Eight trials reported long-term follow-up (<LINK REF="STD-Bergman-1997a" TYPE="STUDY">Bergman 1997a</LINK>; <LINK REF="STD-Ochi-1999" TYPE="STUDY">Ochi 1999</LINK>; <LINK REF="STD-Bergman-2001a" TYPE="STUDY">Bergman 2001a</LINK>; <LINK REF="STD-Yasuda-2001" TYPE="STUDY">Yasuda 2001</LINK>; <LINK REF="STD-Natsui-2002" TYPE="STUDY">Natsui 2002</LINK>; <LINK REF="STD-Vlavianos-2003" TYPE="STUDY">Vlavianos 2003</LINK>; <LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>; <LINK REF="STD-Tanaka-2004" TYPE="STUDY">Tanaka 2004</LINK>) with mean duration of follow-up ranging from 6 months to 60 months. However, the long-term results from the <LINK REF="STD-Yasuda-2001" TYPE="STUDY">Yasuda 2001</LINK> trial were excluded because they also included a subset of retrospectively gathered patients and the randomised data could not be separated. Of these trials, one trial (<LINK REF="STD-Bergman-1997a" TYPE="STUDY">Bergman 1997a</LINK>) used 15 days as its time frame for short-term complications while all other studies used the standard 30 days. Therefore, there is a chance that some of those long-term complications may have by our definition actually been short-term complications.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Six trials (<LINK REF="STD-Bergman-1997a" TYPE="STUDY">Bergman 1997a</LINK>; <LINK REF="STD-Bergman-2001a" TYPE="STUDY">Bergman 2001a</LINK>; <LINK REF="STD-Yasuda-2001" TYPE="STUDY">Yasuda 2001</LINK>; <LINK REF="STD-Fujita-2003" TYPE="STUDY">Fujita 2003</LINK>; <LINK REF="STD-Vlavianos-2003" TYPE="STUDY">Vlavianos 2003</LINK>; <LINK REF="STD-DiSario-2004" TYPE="STUDY">DiSario 2004</LINK>) reported adequate generation of allocation sequence. Seven trials (<LINK REF="STD-Bergman-1997a" TYPE="STUDY">Bergman 1997a</LINK>; <LINK REF="STD-Bergman-2001a" TYPE="STUDY">Bergman 2001a</LINK>; <LINK REF="STD-Yasuda-2001" TYPE="STUDY">Yasuda 2001</LINK>; <LINK REF="STD-Natsui-2002" TYPE="STUDY">Natsui 2002</LINK>; <LINK REF="STD-Fujita-2003" TYPE="STUDY">Fujita 2003</LINK>; <LINK REF="STD-Vlavianos-2003" TYPE="STUDY">Vlavianos 2003</LINK>; <LINK REF="STD-DiSario-2004" TYPE="STUDY">DiSario 2004</LINK>) reported adequate allocation concealment. Two trials (<LINK REF="STD-Bergman-1997a" TYPE="STUDY">Bergman 1997a</LINK>; <LINK REF="STD-Bergman-2001a" TYPE="STUDY">Bergman 2001a</LINK>) provided adequate blinding by having a panel of blinded gastroenterologist who were unaware of the treatment allocations to classify and grade all complications. Five trials (<LINK REF="STD-Bergman-1997a" TYPE="STUDY">Bergman 1997a</LINK>; <LINK REF="STD-Bergman-2001a" TYPE="STUDY">Bergman 2001a</LINK>; <LINK REF="STD-Fujita-2003" TYPE="STUDY">Fujita 2003</LINK>; <LINK REF="STD-Vlavianos-2003" TYPE="STUDY">Vlavianos 2003</LINK>; <LINK REF="STD-DiSario-2004" TYPE="STUDY">DiSario 2004</LINK>) reported the use of intention-to-treat analyses and their data appeared to have followed that principle. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<B>Primary outcomes</B>
<BR/>
<B>
<I>Success</I>
</B>
<BR/>Seven trials detailed that EBD is less likely to extract the stone after the first attempt (73.5% versus 80.9%) (RR 0.90, 95% CI 0.84 to 0.97, random-effects model). Only one trial (<LINK REF="STD-Bergman-1997a" TYPE="STUDY">Bergman 1997a</LINK>) included stone recurrence within the first six months with no significant results found when this was subtracted from the success of the individual procedure. </P>
<P>
<I>Subgroup analyses</I>
<BR/>The following subgroups were noted to yield a significant result demonstrating EBD is less likely to extract the stone after the first attempt: balloon size less than 8 cm, stone size less than 10 cm, age less than 60, age greater than 60, dilation time 45 to 60 seconds, and Asian trials. </P>
<P>
<I>Post hoc analysis</I>
<BR/>Thirteen trials reported rates of overall success showing that EBD is slightly less successful than ES for stone removal when repeated procedures of the same type are allowed (90.1% versus 95.3%) (RR 0.96, 95% CI 0.93 to 0.98, random-effects model). It was also more likely that EBD would be switched to an alterative procedure, most commonly being ES (7.3% versus 0.3%) (RR 8.29, 95% CI 3.28 to 21.00, random-effects). </P>
<P>
<B>Primary adverse event outcomes</B>
<BR/>
<B>
<I>Mortality </I>
</B>
<BR/>Seven trials reported mortality within the first 30 days of the procedure with no significant difference between the two groups (0.7% versus 0.3%) (RR 1.61, 95% CI 0.43 to 6.06, fixed-effect). Rates of overall long-term mortality were not available for analysis as they were not reported in any of the trials.</P>
<P>
<I>Subgroup analyses</I>
<BR/>None of the subgroup analyses yielded significant results as well.</P>
<P>
<B>
<I>Pancreatitis</I>
</B>
<BR/>Fourteen trials commented on the incidence of pancreatitis with a significant higher occurrence of total (overall) pancreatitis in patients treated with EBD than with ES (8.6% versus 4.3%) (RR 1.98, 95% CI 1.35 to 2.90, fixed-effect). In total, mild pancreatitis comprised the majority of the cases when they were dichotomized to mild, moderate, and severe. </P>
<P>
<I>Subgroup analyses</I>
<BR/>The following subgroups yielded a significant result demonstrating a higher occurrence of total pancreatitis in patients treated with EBD than with ES: balloon size less than 8 cm, those using adequate allocation concealment, those using adequate allocation sequence, those using follow-up (intention to treat), and age less than 60 years old. Also of note, Western trials demonstrated a significantly higher occurrence of pancreatitis in the EBD group (10.0% versus 3.8%) (RR 2.71, 95% CI 1.09 to 6.72, random-effects).</P>
<P>
<B>
<I>Bleeding</I>
</B>
<BR/>Twelve trials commented on the occurrence of bleeding with a significantly lower occurrence of major bleeding in patients treated with EBD than with ES (0.1% versus 4.8%) (RR 0.15, 95% CI 0.06 to 0.39, random-effects).</P>
<P>
<I>Subgroup analysis</I>
<BR/>All subgroups (except a dilation time less than 45 sec, anatomic variance) noted a significant result demonstrating a lower rate of major bleeding in patients with EBD than with ES.</P>
<P>
<B>
<I>Perforation</I>
</B>
<BR/>Nine trials commented on the incidence of perforation with no significant difference between the two groups (0.3% versus 0.5%) (RR 0.78, CI 95% 0.17 to 3.46, fixed-effect).</P>
<P>
<I>Subgroup analyses</I>
<BR/>Subgroup analyses also did not yield any significant results.</P>
<P>
<B>
<I>Infection</I>
</B>
<BR/>Fourteen trials commented on the incidence of infection, demonstrating a significantly lower rate of short-term total infection (cholangitis, non cholangitis, cholecystitis) in the EBD group compared with the ES group (2.5% versus 5.0%) (RR 0.55, 95% CI 0.31 to 0.96, random-effects). Further <I>post hoc</I> subgrouping of this demonstrated that EBD carries a lower risk of subsequent short-term cholecystitis if the gall bladder is left <I>in situ</I> as compared with ES (0.1% versus 0.5%) (RR 0.29, 95% CI 0.12 to 0.68, random-effects). However, there was no significant difference in the occurrence of biliary or nonbiliary infections. </P>
<P>
<I>Subgroup analyses</I>
<BR/>The following subgroups yielded a significant result demonstrating a significantly lower rate of total infections: those using adequate allocation sequence, those using intention to treat, and age less than 60 years old.</P>
<P>
<B>
<I>Total combined primary adverse events</I>
</B>
<BR/>All fifteen trials were included with no statistically significant results for total primary adverse events (10.5% versus 9.9%) (RR 1.01, 95% CI 0.62 to 1.63, random-effects model). There was significant heterogeneity by chi-squared testing. Therefore only the random-effects model is noted. </P>
<P>
<I>Subgroup analyses</I>
<BR/>Subgroup analyses also did not yield any significant results.</P>
<P>
<B>Secondary short-term adverse events</B>
<BR/>When all fifteen trials were combined there was no statistically significant result for total short-term complications (12.1% versus 12.7%) (RR 0.96, 95% CI 0.75 to 1.23, fixed-effect model). With total short-term complications there was significant heterogeneity by chi-squared testing. Therefore, only the random-effects model is noted. Only six trials commented on secondary adverse events with no significant difference noted (3.5% versus 3.0%) (RR 1.24 95% CI 0.61 to 2.50, fixed-effect). There was inadequate data to analyse separately the various secondary adverse event outcomes, such as occurrence of pneumonia, adverse reactions to interventions, or others as defined by each trial as had been planned.</P>
<P>
<I>Subgroup analyses</I>
<BR/>Subgroup analyses also did not yield any significant results.</P>
<P>
<B>Other secondary outcomes</B>
<BR/>
<B>
<I>Long-term complications</I>
</B>
<BR/>Seven trials assessed long-term infections with follow-up ranging from 6 to 60 months. Both total long-term infections (2.4% versus 5.8%) (RR 0.44, 95% CI 0.21 to 0.91, fixed-effect) (RR 0.43 (0.18 to 1.06), random-effects) and total long-term complications (9.7% versus 14.0%) (RR 0.69, 95% CI 0.48 to 0.98, fixed-effect) (RR 0.72, 0.50 to 1.03, random-effects) were found to be significantly reduced in the patients undergoing EBD only when a fixed-effect model was applied. Using only the fixed-effect model is acceptable given that no heterogeneity was detected by chi-squared testing. When total infections were divided into cholangitis and acute cholecystitis, only acute cholecystitis demonstrated a significant result with a lower occurrence in the EBD group than in the ES group (1.3% versus 5.0%) (RR 0.29, 95% CI 0.10 to 0.81, random-effects). </P>
<P>
<I>Subgroup analysis</I>
<BR/>The following subgroups yielded a significant result demonstrating lower occurrence of long-term infections when EBD was used as compared with ES: dilation time 45 to 60 seconds, dilation time more than 60 seconds, and Asian trials.</P>
<P>
<B>
<I>Other long-term complications</I>
</B>
<BR/>Stone recurrence was the only other long-term complication with data to support an analysis with no significant difference between the EBD and ES groups (5.5% versus 5.7%) (RR 0.97, 95% CI 0.57 to 1.64, fixed-effect model). Only one trial (<LINK REF="STD-Ochi-1999" TYPE="STUDY">Ochi 1999</LINK>) commented on the occurrence of long-term biliary stricture with no events occurring in either group. Otherwise, there were no trials that noted bile duct malignancy on follow-up. Three trials (<LINK REF="STD-Minami-1995" TYPE="STUDY">Minami 1995</LINK>; <LINK REF="STD-Ochi-1999" TYPE="STUDY">Ochi 1999</LINK>; <LINK REF="STD-Yasuda-2001" TYPE="STUDY">Yasuda 2001</LINK>) all found EBD more likely to preserve sphincter function. However, it was not within the scope of this study to examine these data.</P>
<P>
<I>Subgroup analyses</I>
<BR/>Subgroup analyses also did not yield any significant results.</P>
<P>
<B>
<I>Cost</I>
</B>
<BR/>No trials provided data regarding cost.</P>
<P>
<B>Post hoc analyses of mechanical lithotripsy</B>
<BR/>
<B>
<I>Mechanical lithotripsy</I>
</B>
<BR/>Thirteen trials examined the rates of mechanical lithotripsy demonstrating that EBD requires mechanical lithotripsy significantly more often than ES (20.0% versus 13.3%) (RR 1.34, 95% CI 1.08 to 1.66, random-effects). </P>
<P>
<B>Funnel plots</B>
<BR/>Only funnel plots for total long-term complications showed potential bias.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-16 17:58:24 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Our results yielded significant data on the benefits and potential risks of EBD versus ES for common bile duct stone removal. It was not surprising that EBD carries no risk of bleeding compared with an increased risk with ES. As EBD uses mechanical dilation of the sphincter of Oddi while ES involves a cut, bleeding is avoided in EBD. Therefore, EBD likely carries significant benefits over ES in patients with coagulopathy.<BR/>
<BR/>EBD also is noted to carry less risk for short-term infections when a random-effects model is applied and to carry less risk for long-term infections, and total overall long-term complications when a fixed-effect model is applied. In this case it is reasonable to have confidence in our results using a fixed-effect model as chi-squared testing did not reveal any heterogeneity. For years proponents have argued that EBD preserves the biliary sphincter and therefore decreases the risk of bacterial contamination of the biliary tree, and these decreased risks of short- and long-term infections likely corroborate the clinical significance of these claims. When examining our analysis of short- and long-term infections the most significant impact EBD had in both groups was on lowering the risk of cholecystitis, and it appears likely that this variable significantly influenced the rates of overall infection. This is demonstrated by the fact that the RR for cholangitis and nonbiliary infection fell equally around 1.0, while the risk of cholecystitis heavily weighed the total (overall) rate of infection. This is an important concern in any patients with intact gallbladders, especially in those who will not undergo cholecystectomy. Also in regards to total long-term complications, trials showed a tendency to decreased occurrence in the EBD group. It is this decreased risk of long-term complications, which most proponents of EBD emphasize.</P>
<P>More importantly, the question remains regarding how these complications impact patient's quality of life and overall mortality. Unfortunately, none of these randomised trials addressed that issue, and it is unlikely that any similar trials in the future will do so. In addition, there were no recorded occurrences of biliary malignancy. As some theorize that rates of bile duct malignancy may be decreased with EBD and increased with ES, they occur infrequently and over long periods of time. Furthermore, the total number of patients studied is too small and the trials too short in duration to draw any meaningful conclusions.</P>
<P>Many endoscopists in US and various parts of the world have abandoned the use of EBD as a result of fears of increased risks of pancreatitis. Our analyses verified this fear. However, the more important question is whether this fear of pancreatitis ultimately translates into worse patient outcomes. It is still questionable from our analyses whether this increased risk of pancreatitis lends toward an increase in mortality. In fact, when our analysis examined overall mortality there was no statistically significant difference between EBD and ES. This evidence may negate the claims demonstrated in the <LINK REF="STD-DiSario-2004" TYPE="STUDY">DiSario 2004</LINK> trial. However, others may argue that although 1768 patients were included in our analyses this number may still have been too small to evaluate mortality, which carries a known low incidence with ERCP.</P>
<P>It is also interesting that pancreatitis carries more risks in the subgroup analysis for both Western trials and age of participants less than 60 years. When examined closely, these two groups compose roughly the same trials, indicating that Western trials enrolled younger participants. Conversely, Asian trials which comprised older participants (mean age greater than 60 years) carried no significantly increased risk of pancreatitis. It is unclear whether this association may be secondary strictly to age or other factors. It is also important to emphasize that this subgroup analysis using age was a <I>post-hoc</I> decision and used an arbitrary age point. Therefore, the association from this analysis may very well be confounded.</P>
<P>Unfortunately, it was impossible to analyse whether length of time of balloon dilation and/or number of times of balloon dilation played significant roles in rates of pancreatitis as each trial used differing lengths of balloon dilation and numbers of balloon dilations. In addition, when all trials were subgrouped along the lines of trial quality yielding a mixture of high-quality Western and Asian trials all but blinding (which only included the two Bergman trials) corroborated this increased risk of pancreatitis. Overall pancreatitis is a complication that typically would like to be avoided by most endoscopists, but to avoid using EBD altogether because of these fears may be unreasonable in certain populations.</P>
<P>Our analysis demonstrated the inferiority of EBD to ES regarding a number of other outcomes. EBD is slightly less successful overall in regards to stone removal (EBD 90.1% versus ES 95.3%). This 5.3% difference may seem trivial, however, this rate included the use of multiple repeat procedures. When ductal clearance was evaluated after first attempt, EBD was even less successful. Also as EBD is less successful, it not surprisingly requires a higher rate of an alternative procedure, which is most typically ES. It is well accepted that EBD creates a smaller passage for clearance of bile duct stones compared with ES and EBD may not destroy the biliary sphincter. Because of this, our analysis clearly finds that EBD consequently carries a higher rate of mechanical lithotripsy for stone clearance in conjunction with this need for repeated dilations.</P>
<P>Since the rates of perforation were so low no significant difference could be demonstrated between EBD and ES. Also, unfortunately no data were available on cost, quality scores, and length of hospital stay.</P>
<P>A meta-analysis (<LINK REF="REF-Baron-2004" TYPE="REFERENCE">Baron 2004</LINK>) was published during the preparation of the present systematic review. Baron's et al study included only eight of our fifteen trials due to their language and publication type restrictions. Similarly to our study their outcomes included pancreatitis, bleeding, infection, perforation and death; however, they only examined these events within the first twenty-four hours. Both meta-analyses found a similar increased risk of pancreatitis and decreased risk of bleeding with EBD compared with ES. Also, both meta-analyses found EBD to be significantly less successful overall for stone extraction; however, only our analysis found this to be statistically significant. Our analyses also go further by not only subdividing different outcomes into various subgroups (ie, mild, moderate, severe pancreatitis) but by also examining similar and other outcomes over the first 30 days and beyond.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Our meta-analysis confirms that EBD is slightly less successful than ES in stone extraction. EBD is more likely to induce pancreatitis. However, in spite of the fear of death from pancreatitis caused by EBD, there is no convincing evidence that in regards to mortality EBD is more risky than ES. Furthermore, EBD appears to be superior to ES in patients who have prolonged bleeding times, who are at risk for infection, and possibly in those who are older. If the use of EBD is desired then the risks and benefits as compared with ES should be discussed with the patient.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further trials are necessary to assess the risks and benefits of EBD compared with ES in selected populations (those prone to bleeding and those at risk for infection). Although roughly half of the previously conducted trials were designed with adequate randomisation, allocation concealment, and intention-to-treat methods, only two provided adequate blinding of outcome assessment. Therefore, future trials should not only focus on adequate generation of the allocation sequence, allocation concealment, and intention-to-treat methodologies, but also incorporate adequate blinding of those who follow-up the patients after the intervention. Also, given the low incidence of many of these outcomes attempts at adequately powered trials are necessary to truly answer these questions. Future trials ought to be reported following the recommendations of the CONSORT Statement (www.consort-statement.org).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Special thanks to Janice L. Contini, Head Reference Librarian at the UCLA, and Louise M. Darling Biomedical Library, who helped us develop our search strategy. Special thanks also to Janet D. Elashoff, Ph.D., Director of Biostatistics Core Research Institute at Cedars-Sinai Medical Center, who helped us develop our statistical approaches for carrying out our analyses. Special thanks to Dr. Dong Ki Lee who provided a Korean to English translation for one of the articles. Great thanks to Dr. Ronald Koretz, Chief of Gastroenterology at UCLA - Olive View Medical Center, who contributed significant mentoring to the development of the protocol and to the final systematic review. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Benjamin Weinberg: principle investigator/primary author.<BR/>Waleed Shindy: second author.<BR/>Simon Lo: advisor/third author.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-16 17:59:58 +0100" MODIFIED_BY="dimitrinka nikolova">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnold-2001" NAME="Arnold 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnold JC, Benz C, Martin WR, Adamek HE, Riemann JF</AU>
<TI>Endoscopic papillary balloon dilation vs. sphincterotomy for removal of common bile duct stones: a prospective randomized pilot study</TI>
<SO>Endoscopy</SO>
<YR>2001</YR>
<VL>33</VL>
<PG>563-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergman-1997a" NAME="Bergman 1997a" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergman JJ, Rauws E, Fockens P, Van Berkel A, Bossuyt P, Tijssen J, et al</AU>
<TI>Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bile duct stones</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>1124-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergman-2001a" NAME="Bergman 2001a" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergman JJ, van Berkel AM, Bruno MJ, Fockens P, Raws EA, Tijssen JG</AU>
<TI>A randomized trial of endoscopic balloon dilation and endoscopic sphincterotomy for removal of bile duct stones in patients with a prior Billroth II gastrectomy</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2001</YR>
<VL>53</VL>
<NO>1</NO>
<PG>19-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1998" NAME="Chen 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen YK, Deguzman l, Godil A, Chang KJ, Walter MH</AU>
<TI>Prospective randomized trial of balloon dilatation versus sphincterotomy for extraction of bile duct stones</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>AB111</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cho-1998" NAME="Cho 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cho JD, Hong SJ, Moon JH, Kim JO, Cho JY, Kim YS, et al</AU>
<TI>Endoscopic papillary balloon dilatation versus endoscopic sphincterotomy for removal of common bile duct stones</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>AB111</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DiSario-2004" NAME="DiSario 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DiSario JA, Freeman JL, Bjorkman DJ, MacMathuna P, Peterson B, Sherman S, et al</AU>
<TI>Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones: preliminary results</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>127</VL>
<PG>1291-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fujita-2003" NAME="Fujita 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fujita N, Maguchi H, Komatsu Y, Yasuda I, Hasebe O, Igarashi Y, et al</AU>
<TI>Endscopic sphincterotomy and endoscopic papillary balloon dilatation for bile duct stones: a prospective randomized controlled multicenter trial</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2003</YR>
<VL>57</VL>
<PG>151-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwata-1998" NAME="Iwata 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iwata F, Miyaki T, Yamada J, Joh T, Itoh M</AU>
<TI>Effect of endoscopic papillary balloon dilation for the management of common bile duct stones in the elderly</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>114</VL>
<PG>A524</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2004" NAME="Lin 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin CK, Lai KH, Chan HH, Tsai WL, Wang EM, Wei MC, et al</AU>
<TI>Endoscopic balloon dilation is a safe method in the management of common bile duct stones</TI>
<SO>Digestive and Liver Disease</SO>
<YR>2004</YR>
<VL>36</VL>
<PG>68-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minami-1995" NAME="Minami 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minami A, Nakatsu T, Uchida N, Hirabayashi S, Fukuma H, Morshed SA, et al</AU>
<TI>Papillary dilation vs sphincterotomy in endoscopic removal of bile duct stones - a randomized trial with manometric function</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1995</YR>
<VL>40</VL>
<PG>2550-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Natsui-2002" NAME="Natsui 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Natsui M, Narisawa R, Motoyama H, Hayashi S, Seki K, Wakabayashi H, et al</AU>
<TI>What is the appropriate indication for endoscopic papillary balloon dilation?</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2002</YR>
<VL>14</VL>
<PG>635-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ochi-1999" NAME="Ochi 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ochi Y, Mukawa K, Kiyosawa K, Akamatsu T</AU>
<TI>Comparing the treatment outcomes of endoscopic papillary dilation and endoscopic sphincterotomy for removal of bile duct stones</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>90-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanaka-2004" NAME="Tanaka 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanaka S, Sawayama T, Yoshioka T</AU>
<TI>Endoscopic papillary balloon dilation and endoscopic sphincterotomy for bile duct stones: long-term outcomes in a prospective randomized controll trial</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>6</NO>
<PG>614-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vlavianos-2003" NAME="Vlavianos 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vlavianos P, Chopra K, Mandalia S, Anderson M, Thompson J, Westaby D</AU>
<TI>Endoscopic balloon dilatation versus endoscopic sphincterotomy for the removal of bile duct stones: a prospective randomized trial</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<PG>1165-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yasuda-2001" NAME="Yasuda 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yasuda I, Tomita E, Enya M, Kato T, Moriwaki H</AU>
<TI>Can endoscopic papillary balloon dilation really preserve sphincter of Oddi function?</TI>
<SO>Gut</SO>
<YR>2001</YR>
<VL>49</VL>
<PG>686-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Adamek-1997" NAME="Adamek 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adamek, R</AU>
<TI>Endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bile duct stones</TI>
<SO>Zeitschrift fur Gastroenterologie</SO>
<YR>1997</YR>
<VL>35</VL>
<PG>253-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aizawa-2001" NAME="Aizawa 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aizawa T, Ueno N</AU>
<TI>Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones</TI>
<SO>Gastrointestinal Endscopy</SO>
<YR>2001</YR>
<VL>54</VL>
<PG>209-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergman-1997b" NAME="Bergman 1997b" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergman J, Huibregtse K</AU>
<TI>Endoscopic balloon dilatation of the biliary sphincter for removal of bile duct stones: description of endscopic technique and a review of the literature</TI>
<SO>Acta Endoscopica</SO>
<YR>1997</YR>
<VL>27</VL>
<PG>405-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergman-1998" NAME="Bergman 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergman JJ, Tytgat GN, Huibregtse K</AU>
<TI>Endoscopic dilatation of the biliary sphincter for removal of bile duct stones: an overview of current indications and limitations</TI>
<SO>Scandinavian Journal of Gastroenterology Supplement</SO>
<YR>1998</YR>
<VL>225</VL>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhasin-1999" NAME="Bhasin 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhasin DK, Sinha SK</AU>
<TI>Comparing the treatment outcomes of endoscopic papillary dilation and endoscopic sphincterotomy for removal of bile duct stones</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1999</YR>
<VL>50</VL>
<PG>886-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cho-1998b" NAME="Cho 1998b" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cho YD, Hong SJ, Moon JH, Kim JO, Cho JY, Kim YS, et al</AU>
<TI>Clinical usefulness of intraductal ultrasonography on detection of small remnant stones after endoscopic papillary balloon dilatation</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>AB111</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DiSario-2003a" NAME="DiSario 2003a" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DiSario JA</AU>
<TI>Endoscopic balloon dilatation for extraction of bile duct stones: the devil is in the details</TI>
<SO>Gastrointestinal Endscopy</SO>
<YR>2003</YR>
<VL>57</VL>
<PG>151-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huibregtse-1999" NAME="Huibregtse 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huibregtse K</AU>
<TI>Biliary sphincter balloon dilation; who, when, and how?</TI>
<SO>Canadian Journal of Gastroenterology</SO>
<YR>1999</YR>
<VL>13</VL>
<PG>499-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ido-1997" NAME="Ido 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ido K, Tamada K, Kimura K, Oohashi A, Ueno N, Kawamoto C</AU>
<TI>The role of endoscopic balloon sphincteroplasty in patient with gallbladder and bile duct stones</TI>
<SO>Journal of Laparoendoscopic &amp; Advanced Surgical Techniques. Part A</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalinsky-1999a" NAME="Kalinsky 1999a" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalinsky E, Prat F, Boyer J, Pelletier G, Fritsch J, Choury AD, et al</AU>
<TI>Endoscopic sphincteroclasty for choledochilithiasis of the principal bile duct. Short-term results and follow-up</TI>
<SO>Gastroenterologie Clinique et Biologique</SO>
<YR>1999</YR>
<VL>23</VL>
<PG>187-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawabe-1996a" NAME="Kawabe 1996a" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawabe T, Komatsu Y, Tada M, Toda N, Ohashi M, Shiratori Y, et al</AU>
<TI>Endoscopic papillary balloon dilation in cirrhotic patients: removal of common bile duct stones without sphincterotomy</TI>
<SO>Endoscopy</SO>
<YR>1996</YR>
<VL>28</VL>
<PG>694-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komatsu-1997a" NAME="Komatsu 1997a" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Komatsu Y, Kawabe T, Isayama H, Koike Y, Toda N, Ohashi M, et al</AU>
<TI>Endoscopic papillary balloon dilation for the management of common bile duct stones: experience of 207 cases including high risk patients</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1997</YR>
<VL>45</VL>
<NO>4</NO>
<PG>AB137</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komatsu-1998a" NAME="Komatsu 1998a" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Komatsu Y, Kawabe T, Toda N, Ohashi M, Isayama H, Tateishi K, et al</AU>
<TI>Endoscopic papillary balloon dilation for the management of common bile duct stones: experience of 226 cases</TI>
<SO>Endoscopy</SO>
<YR>1998</YR>
<VL>30</VL>
<PG>12-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komatsu-1998b" NAME="Komatsu 1998b" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Komatsu Y, Kawabe T, Ijichi T, Isayama H, Yamagata M, Tada M, et al</AU>
<TI>Endoscopic papillary balloon dilation using a long tip balloon catheter for the management of common bile duct stone</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>AB120</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komatsu-2000" NAME="Komatsu 2000" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Komatsu Y, Sasahira N, Isayama H, Toda N, Tada M, Ohashi M, et al</AU>
<TI>Endoscopic papillary balloon dilation in cirrhotic patients for the managment of common bile duct stones</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2000</YR>
<VL>51</VL>
<PG>AB190</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komatsu-2001a" NAME="Komatsu 2001a" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Komatsu Y, Sasahira N, Hirano K, Isayama H, Toda N, Tsujino T, et al</AU>
<TI>Long-term results of endoscopic papillary balloon dilation for the management of common bile duct stones</TI>
<SO>Gastroinestinal Endoscopy</SO>
<YR>2001</YR>
<VL>53</VL>
<PG>AB86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mac-Mathuna-1995" NAME="Mac Mathuna 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mac Mathuna P, White P, Clarke E, Merriman R, Lennon JR, Crowe J</AU>
<TI>Endoscopic balloon sphincterplasty (EBS) reduces the need for papillotomy: 2 year follow-up in 100 patients</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1995</YR>
<VL>41</VL>
<PG>406</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsumoto-2001" NAME="Matsumoto 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsumoto H, Araki M, Kawanishi N, Matsuzaki Y, Nakahara A, Tanaka N, et al</AU>
<TI>Shortened duration of balloon dilatation may reduce the indicence of pancreatitis and the elevation of serum amylase after endoscopic papillary balloon dilatation for extracting bile duct stones</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2001</YR>
<VL>53</VL>
<PG>AB100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moon-2001" NAME="Moon 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moon J, Cho Y, Jung I, Cheon Y, Kim Y, Lee S, et al</AU>
<TI>The usefulness of the endoscopic papillary balloon dilation in patients with Billroth II gastrectomy for management of bile duct stones</TI>
<SO>Gastrointestinal Endscopy</SO>
<YR>2001</YR>
<VL>53</VL>
<PG>AB98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohashi-1999a" NAME="Ohashi 1999a" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;A. Ohashi, K. Tamada, T. Tomiyama, T. Aizawa, S. Wada, T. Miyata, T. Nishizono, S. Tano, Y. Sato, N. Ueno, K. Ido, K. Kimura&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohashi A, Tamada K, Tomiyama T, Aizawa T, Wada S, Miyata T, et al</AU>
<TI>Influence of bile duct diameter on the therapeutic quality of endocopic balloon sphincteroplasty</TI>
<SO>Endoscopy</SO>
<YR>1999</YR>
<VL>31</VL>
<PG>137-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohashi-1999b" NAME="Ohashi 1999b" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohashi A, Ueno N, Tamada K, Tomiyama T, Wada S, Miyata T, et al</AU>
<TI>Assessment of residual bile duct stones with use of intraductal US during endoscopic balloon sphincteroplasty: comparision with balloon cholangiography</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1999</YR>
<VL>49</VL>
<PG>328-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohashi-2001" NAME="Ohashi 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohashi A, Tamada K, Tomiyama T, Wada S, Higashizawa T, Gotoh Y, et al</AU>
<TI>Epinephrine irrigation for the prevention of pancreatic damage after endoscopic balloon sphincteroplasty</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2001</YR>
<VL>16</VL>
<PG>561-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-2004" NAME="Park 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park DO, Kim MH, Lee SK, Lee SS, Choi JK, Song MH, et al</AU>
<TI>Endoscopic sphincterotomy vs endoscopic papillary balloon dilation for choledocholithiasis in patients with liver cirrhosis and coagulopathy</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2004</YR>
<VL>60</VL>
<NO>2</NO>
<PG>180-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prat-2002" NAME="Prat 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prat F, Amaris J, Ducot B, Bocquentin M, Fritsch J, Choury AD, et al</AU>
<TI>Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blinded randomized study</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2002</YR>
<VL>56</VL>
<PG>202-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pugliese-1997" NAME="Pugliese 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pugliese V</AU>
<TI>Endoscopic sphincterotomy (ES) vs endoscopic balloon dilatation (EBD) for bile duct stones (BDS). Results in 28 patients under 56 years of age</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1997</YR>
<VL>45</VL>
<PG>AB 144</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roncoroni-1986" NAME="Roncoroni 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roncoroni L, De Bernardinis M, Violi V, Montanari M, Peracchia A</AU>
<TI>Effect of perioperative somatostatin administration of sphincteroplasty-induced increase of amylase</TI>
<SO>American Journal of Gstroenterology</SO>
<YR>1986</YR>
<VL>81</VL>
<PG>432-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sato-1996" NAME="Sato 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato H, Mitsufuji S, Takaaki J, Tatsumi Y, Maeda T, Fukita S</AU>
<TI>Effect of endoscopic balloon sphincteroplasty (EBS) on sphincter of Oddi-evaluation from the view point of endoscopic manometry</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1996</YR>
<VL>43</VL>
<PG>394</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sato-1997" NAME="Sato 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato H, Kodama T, Takaaki J, Tatsumi Y, Imamura Y, Maeda T, et al</AU>
<TI>Endoscopic papillary balloon dilation (EPBD) may preserve sphincter of Oddi (SO) function</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1997</YR>
<VL>45</VL>
<PG>AB147</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takahata-1999" NAME="Takahata 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takahata S, Nabae T, Yokohata K, Konomi H, Utsunomiya N, Matsunaga H, et al</AU>
<TI>Function of spincter of Oddi (S0) after balloon dilatation: detailed manometric evaluation in conscious dogs</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1999</YR>
<VL>49</VL>
<PG>AB228</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wantanbe-2004" NAME="Wantanbe 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watanabe H, Hiraishi H, Koitabashi A, Sasai T, Kanke K, Oinuma T, et al</AU>
<TI>Endoscopic papillary balloon dilation for treatment of common bile duct stones</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>2004</YR>
<VL>51</VL>
<PG>652-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yasuda-1998a" NAME="Yasuda 1998a" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yasuda I, Tomita E, Moriwaki H, Kato T, Wakahara T, Sugihara J</AU>
<TI>Endoscopic papillary balloon dilatation for common bile duct stones: efficacy of combination with extracorporeal shockwave lithotripsy for large stones</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>1998</YR>
<VL>10</VL>
<PG>1045-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Yasuda-1998b" NAME="Yasuda 1998b" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yasuda I, Tomita E, Moriwaki H</AU>
<TI>Endoscopic papillary balloon dilation (EPBD) for multiple or large common bile duct stones. ESWL may reduce the risk of pancreatitis</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>AB132</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yasuda-1999" NAME="Yasuda 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yasuda I, Tomita E, Adachi S, Toda K, Naiki T, Enya M, et al</AU>
<TI>Can endoscopic papillary balloon dilation (EPBD) preserve the sphincter of Oddi function?</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1999</YR>
<VL>49</VL>
<PG>AB228</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-16 17:59:58 +0100" MODIFIED_BY="dimitrinka nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-16 17:59:58 +0100" MODIFIED_BY="dimitrinka nikolova">
<REFERENCE ID="REF-Baron-2004" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Baron 2004" TYPE="JOURNAL_ARTICLE">
<AU>Baron T, Harewood C</AU>
<TI>Endoscopic balloon dilation of the biliary sphincter compared to endoscopic biliary sphincterotomy for removal of common bile duct stones during ERCP: a metaanalysis of randomized, controlled trials</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2004</YR>
<VL>99</VL>
<PG>1455-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergman-1996" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Bergman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bergman JJ, Van der Mey S, Rauws E, Tijssen JG, Gouma DJ, Tytgat GN, et al</AU>
<TI>Long-term follow-up after endoscopic sphincterotomy for bile duct stones in patients younger than 60 years of age</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1996</YR>
<VL>44</VL>
<PG>643-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergman-2001b" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Bergman 2001b" TYPE="JOURNAL_ARTICLE">
<AU>Bergman JJ, van Berkel AM, Bruno MJ, Fockens P, Raws EA, Tijssen JG</AU>
<TI>A randomized trial of endoscopic balloon dilation and endoscopic sphincterotomy for removal of bile duct stones in patients with a prior Billroth II gastrectomy</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2001</YR>
<VL>53</VL>
<NO>1</NO>
<PG>19-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Classen-1974" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Classen 1974" TYPE="JOURNAL_ARTICLE">
<AU>Classen M, Demling L</AU>
<TI>Endoscopic sphincterotomy of the papilla of Vater and extraction of stones from the choledochal duct</TI>
<TO>Endoskopische Sphinkterotomie der Papilla Vateri und Steinextraktion aus dem Ductus choledochus</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1974</YR>
<VL>99</VL>
<PG>496-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cotton-1991" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Cotton 1991" TYPE="JOURNAL_ARTICLE">
<AU>Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC</AU>
<TI>Endoscopic sphincterotomy complications and their management: an attempt at consensus</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1991</YR>
<VL>37</VL>
<PG>383-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DiSario-1997" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="DiSario 1997" TYPE="JOURNAL_ARTICLE">
<AU>DiSario JA, Freeman JL, Bjorkman DJ, MacMathuna P, Peterson B, Sherman S, et al</AU>
<TI>Endoscopic balloon dilation compared to sphincterotomy (EDES) for extraction of bile duct stones: preliminary results</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1997</YR>
<VL>45</VL>
<PG>AB129</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DiSario-1999" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="DiSario 1999" TYPE="JOURNAL_ARTICLE">
<AU>DiSario JA, Freeman ML, Bjorkman DJ, MacMathuna P, Petersen B, Sherman S, et al</AU>
<TI>Endoscopic balloon dilation vs. sphincterotomy (EDES) bile duct stone removal</TI>
<SO>Digestion</SO>
<YR>1999</YR>
<VL>59</VL>
<NO>suppl 3</NO>
<PG>26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freeman-1996" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Freeman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al</AU>
<TI>Complications of endoscopic biliary sphincterotomy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>335</VL>
<PG>909-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldman-1983" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Goldman 1983" TYPE="JOURNAL_ARTICLE">
<AU>Goldman LD, Steer ML, Silen W</AU>
<TI>Recurrent cholangitis after biliary surgery</TI>
<SO>American Journal of Surgery</SO>
<YR>1983</YR>
<VL>145</VL>
<PG>450-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gottlieb-1998" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Gottlieb 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gottlieb K, Sherman S</AU>
<TI>ERCP and endoscopic biliary sphincterotomy-induced pancreatitis</TI>
<SO>Gastrointestinal Endoscopy Clinics of North America</SO>
<YR>1998</YR>
<VL>8</VL>
<PG>87-115</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenfield-1985" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Greenfield 1985" TYPE="JOURNAL_ARTICLE">
<AU>Greenfield C, Cleland P, Dick R, Masters S, Summerfield JA, Sherlock S, et al</AU>
<TI>Biliary sequelae of endoscopic sphincterotomy</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1985</YR>
<VL>61</VL>
<PG>213-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gregg-1985" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Gregg 1985" TYPE="JOURNAL_ARTICLE">
<AU>Gregg JA, De Girolami P, Carr Locke DL</AU>
<TI>Effects of sphincteroplasty and endoscopic sphincterotomy on the bacteriologic characteristics of the common bile duct</TI>
<SO>American Journal of Surgery</SO>
<YR>1985</YR>
<VL>149</VL>
<PG>669-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Groen-1989" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Groen 1989" TYPE="JOURNAL_ARTICLE">
<AU>Groen JN, Lock MT, Lameris JS, van Blankenstein M, Terpstra OT</AU>
<TI>Removal of bile duct stones by the combination of percutaneous balloon dilation and extracorporeal shock-wave lithotripsy</TI>
<SO>Gastroenterology</SO>
<YR>1989</YR>
<VL>97</VL>
<NO>1</NO>
<PG>202-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hawes-1990" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Hawes 1990" TYPE="JOURNAL_ARTICLE">
<AU>Hawes RH, Cotton PB, Vallon AG</AU>
<TI>Follow-up 6 to 11 years after duodenoscopic sphincterotomy for stones in patients with prior cholecystectomy</TI>
<SO>Gastroenterology</SO>
<YR>1990</YR>
<VL>98</VL>
<NO>4</NO>
<PG>1008-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heinerman-1994" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Heinerman 1994" TYPE="JOURNAL_ARTICLE">
<AU>Heinerman PM, Graf AH, Boeckl O</AU>
<TI>Does endoscopic sphincterotomy destroy the function of Oddi's sphincter?</TI>
<SO>Archives of Surgery</SO>
<YR>1994</YR>
<VL>129</VL>
<PG>876-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-10-16 17:59:58 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Kjaergard 2001" NOTES="&lt;p&gt;Kjaergard LL, Villumsen J, Gluud C Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:59:58 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurumado-1994" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Kurumado 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kurumado K, Nagai T, Kondo Y, Abe H</AU>
<TI>Long-term observations of morphological changes of choledochal epithelium after choledochoenterostomy in rats</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1994</YR>
<VL>39</VL>
<PG>809-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacMathuna-1994" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="MacMathuna 1994" TYPE="JOURNAL_ARTICLE">
<AU>MacMathuna P, White P, Clarke E, Lennon J, Crowe J</AU>
<TI>Endoscopic sphincterotomy: a novel and safe alternative of pallilotomy in the management of bile duct stones</TI>
<SO>Gut</SO>
<YR>1994</YR>
<VL>35</VL>
<PG>127-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacMathuna-1995" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="MacMathuna 1995" TYPE="JOURNAL_ARTICLE">
<AU>MacMathuna P, White P, Clarke E, Merriman R, Lennon J, Crowe J</AU>
<TI>Endscopic balloon sphincteroplasty (papillary dilation) for bile duct stones: efficacy, safety, and follow-up in 100 patients</TI>
<SO>Gastrointestal Endoscopy</SO>
<YR>1995</YR>
<VL>42</VL>
<PG>468-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maki-1966" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Maki 1966" TYPE="JOURNAL_ARTICLE">
<AU>Maki T</AU>
<TI>Pathogenesis of calcium bilirubinate gallstone: role of E. coli, beta-glucuronidase and coagulation by inorganic ions, polyelectrolytes and agitation</TI>
<SO>Annals of Surgery</SO>
<YR>1966</YR>
<VL>164</VL>
<PG>90-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-May-1993" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="May 1993" TYPE="JOURNAL_ARTICLE">
<AU>May GR, Cotton PB, Edmunds S, Chong W</AU>
<TI>Removal of stones from the bile duct at ERCP without sphincterotomy</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1993</YR>
<VL>39</VL>
<PG>749-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-10-16 17:59:58 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad A, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moreira-1991" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Moreira 1991" TYPE="JOURNAL_ARTICLE">
<AU>Moreira VF, Arribas R, Sanroman AL, Merono E, Larena C, Garcia M, et al</AU>
<TI>Choledolithiasis in cirrhotic patients: Is endoscopic sphincteromy the safest choice?</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1991</YR>
<VL>86</VL>
<PG>1006-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2003" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="RevMan 2003" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2003</YR>
<EN>4.2 for Windows</EN>
<PB>Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sand-1992" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Sand 1992" TYPE="JOURNAL_ARTICLE">
<AU>Sand J, Airo I, Hiltunen KM, Mattila J, Nordback I</AU>
<TI>Changes in biliary bacteria after endoscopic cholangiography and sphincterotomy</TI>
<SO>American Surgery</SO>
<YR>1992</YR>
<VL>58</VL>
<PG>324-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-10-16 17:59:58 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Schulz 1995" NOTES="&lt;p&gt;Schulz KF, Chalmers I, Hayes RJ, Altman DG Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 17:59:58 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheth-2001" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Sheth 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sheth SG</AU>
<TI>What are really the true late complications of endoscopic biliary sphincterotomy?</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>97</VL>
<PG>2699-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skar-1986" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Skar 1986" TYPE="JOURNAL_ARTICLE">
<AU>Skar V, Skar AG, Midtvedt T, Lotviet T, Osnes M</AU>
<TI>Bacterial growth in the duodenum and in the bile of patients with gallstone disease treated with endoscopic papillotomy</TI>
<SO>Endoscopy</SO>
<YR>1986</YR>
<VL>18</VL>
<PG>10-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Staritz-1983" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Staritz 1983" TYPE="JOURNAL_ARTICLE">
<AU>Staritz M, Ewe K, Meyer zum Buschenfelde KH</AU>
<TI>Endoscopic papillary dilation (EPD) for the treatment of common bile duct stones and papillary stenosis</TI>
<SO>Endoscopy</SO>
<YR>1983</YR>
<VL>15</VL>
<PG>197-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sugiyama-1993" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Sugiyama 1993" TYPE="JOURNAL_ARTICLE">
<AU>Sugiyama M, Atomi Y, Kuroda A, Muto T</AU>
<TI>Treatment of choledocholisthiasis in patients with liver cirrhosis: surgical treatment or endoscopic sphincterotomy?</TI>
<SO>Annals of Surgery</SO>
<YR>1993</YR>
<VL>218</VL>
<PG>68-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sugiyama-1998" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Sugiyama 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sugiyama M, Atomi Y</AU>
<TI>Follow-up of more than 10 years after endoscopic sphincterotomy for choledocholithiasis in young patients</TI>
<SO>British Journal of Surgery</SO>
<YR>1998</YR>
<VL>85</VL>
<PG>917-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sugiyama-2002" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Sugiyama 2002" TYPE="JOURNAL_ARTICLE">
<AU>Sugiyama M, Atomi Y</AU>
<TI>Risk factors predictive of late complications after endoscopic sphincterotomy for bile duct stones: long term (more than 10 years) follow-up study</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<PG>2763-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanaka-1998" MODIFIED="2008-10-16 17:59:46 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Tanaka 1998" TYPE="JOURNAL_ARTICLE">
<AU>Tanaka M, Takahata S, Konomi H, Matsunaga H, Yokohata K, Taheda T, et al</AU>
<TI>Long-term consequence of endoscopic sphincterotomy for bile duct stones</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1998</YR>
<VL>48</VL>
<PG>465-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-16 18:01:04 +0100" MODIFIED_BY="dimitrinka nikolova">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-10-16 18:01:04 +0100" MODIFIED_BY="dimitrinka nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Arnold-2001">
<CHAR_METHODS>
<P>Randomised clinical trial<BR/>Hospital setting: unclear.</P>
<P>Generation of allocation sequence: unclear.<BR/>Allocation concealment: unclear.<BR/>Blinding: unclear.</P>
<P>Length of follow-up: unclear.<BR/>Intention to treat: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 60<BR/>Germany</P>
<P>Inclusion criteria: stones &lt; 20 mm in size and &lt; 5 in number on fluroscopic exam.</P>
<P>Exclusion criteria: &lt; 18 years of age, bile duct stones &gt; 20 mm, &gt; 5 stones, recurrent bile duct stones, pervious EST.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 8 mm.</P>
<P>Time of balloon dilation: 60 seconds x 2.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Treatment success.<BR/>(2) Stone extraction rate.<BR/>(3) Duration of examination.<BR/>(4) Need to perform EST or EBD in patients with failed extraction.<BR/>(5) Short term complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published manuscript.</P>
<P/>
<P/>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-16 18:01:04 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Bergman-1997a">
<CHAR_METHODS MODIFIED="2008-10-16 18:01:04 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Randomised clinical trial<BR/>Single centre.</P>
<P>Generation of allocation sequence: adequate.<BR/>Allocation concealment: adequate.<BR/>Blinding: not performed.</P>
<P>Length of follow-up: six months.<BR/>Intention-to-treat: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 202<BR/>University setting.<BR/>Netherlands</P>
<P>Inclusion criteria: &gt; 18 year of age, bile stones on ERCP, deep cannulation achieved without sphincterotomy.</P>
<P>Exclusion criteria: acute cholangitis, acute pancreatitis, acute cholecystitis, history of ES, choledochoduodenal fistula, haemostatic disorders, intrahepatic disease, hemolytic anemia, pancreatic or biliary malignancy, coexisting bile leakage or choledochoduodenal fistula, previous participation in this study, and life expectancy &lt; 1 month.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 8 mm.</P>
<P>Time of dilation: inflated over 1-2 minutes then held for 45-60 seconds.</P>
<P>ES done according to standard guidelines by pull-sphincterotomies.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Treatment success.<BR/>(2) Frequency of addition sphincterotomy.<BR/>(3) Frequency of lithotripsy.<BR/>(4) Complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published manuscript.</P>
<P/>
<P/>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-16 18:01:01 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Bergman-2001a">
<CHAR_METHODS MODIFIED="2008-10-16 18:01:01 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Randomised clinical trial<BR/>Single centre</P>
<P>Generation of allocation sequence: adequate.<BR/>Allocation concealment: adequate.<BR/>Blinding: not performed.</P>
<P>Length of follow-up: six months.<BR/>Intention-to-treat: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 34<BR/>University setting<BR/>Netherlands</P>
<P>Patients separated from larger original study and then further participants recruited.</P>
<P>Inclusion criteria: (1) referred for ERCP for symptoms of stones, (2) age &gt;18, (3) informed consent, (4) bile duct stones demonstrated on ERCP, (5) deep cannulation of bile duct achieved without precut sphincterotomy.</P>
<P>Exclusion criteria: signs of acute cholangitis, acute pancreatitis, acute cholecystitis, abdominal pain, history of previous ES, choledochoduodenal fistula, coagulopathy, intrahepatic stone disease, hemolytic anemia, concomitant pancreatic or biliary malignancy, coexisting biliary leakage, previous participation in this study, and life expectancy &lt; 1 month.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 8 mm.</P>
<P>Time of balloon Inflated over 1-2 minutes, then held at max dilation 45-60 seconds.</P>
<P>ES was of performed by needle knife.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Treatment success.<BR/>(2) Short-term complications.<BR/>(3) Long-term complications.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published manuscript.</P>
<P/>
<P/>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chen-1998">
<CHAR_METHODS>
<P>Randomised clinical trial<BR/>Centre type: unclear.</P>
<P>Generation of allocation sequence: unclear.<BR/>Allocation concealment: unclear.<BR/>Blinding: unclear.</P>
<P>Length of follow-up: 30 days.<BR/>Intention-to-treat: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 93<BR/>United States</P>
<P>Inclusion criteria: stones less than or equal to 10 mm.</P>
<P>Exclusion criteria: SO dysfunction, cholangitis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: unclear.</P>
<P>Time of balloon dilation: unclear.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Treatment success.<BR/>(2) Short-term complications.<BR/>(3) Late-term complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract only.</P>
<P/>
<P/>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cho-1998">
<CHAR_METHODS>
<P>Randomised clinical trial<BR/>Centre type: unclear.</P>
<P>Generation of allocation sequence: unclear.<BR/>Allocation concealment: unclear.<BR/>Blinding: unclear.</P>
<P>Length of follow-up: unclear.<BR/>Intention-to-treat: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 84<BR/>Korea</P>
<P>Inclusion and exclusion criteria: not stated.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 8 mm.</P>
<P>Balloon dilation time: 60 or 120 seconds.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Treatment success.<BR/>(2) Complication rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract combined with translated summary . As well as translated by Dr. Dong K Lee<BR/>(Unfortunately full translation of methods section was unobtainable, resulting in inability to assess adequacy of randomisation, allocation concealment, blinding, and intention-to-treat.</P>
<P/>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-16 18:00:18 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-DiSario-2004">
<CHAR_METHODS>
<P>Randomised clinical trial<BR/>Multicentre international study</P>
<P>Generation of allocation sequence: adequate.<BR/>Allocation concealment: adequate.<BR/>Blinding: not performed.</P>
<P>Length of follow-up: 30 days.<BR/>Intention-to-treat: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 18:00:18 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>N = 237</P>
<P>Inclusion criteria: at least 18 yo, known or suspected bile duct stones, and had cholecystectomy previously or planned within 30 days.</P>
<P>Exclusion criteria: acute pancreatitis, septic shock, coagulopathy, platelet count &lt; 50,000, sphincter of Oddi dysfunction, stone diameter &gt;10 mm, bile duct diameter &gt; 15 mm, &gt; 5 stones, prior sphincterotomy, biliary strictures or fistulas, Billroth II or Roux-en-Y anatomy, ampullary tumours, primary sclerosing cholangitis, Caroli's disease, pregnancy, incarceration, inability to give informed consent.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter less than or equal to 8 mm.</P>
<P>Time of dilation: 1 minute.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Treatment success.<BR/>(2) Short-term complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published manuscript.</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fujita-2003">
<CHAR_METHODS>
<P>Randomised clinical trial<BR/>Multicentre</P>
<P>Generation of allocation sequence: <BR/>adequate.<BR/>Allocation concealment: unclear.<BR/>Blinding: not performed.</P>
<P>Length of follow-up: unclear.<BR/>Intention-to-treat: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 282<BR/>Japan</P>
<P>Inclusion criteria: patients with bile duct stones less than or equal to 14 mm<BR/>exclusion criteria: history of ES or EBD, advanced malignancy, hemorrhagic diathesis, severe cardiovascular or neurologic disorder, disseminated intravascular coagulation, poor general condition, septic shock, severe acute pancreatitis, and an impacted stone at the duodenal papilla that was not movable by cannula.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 8 mm. </P>
<P>Time of balloon dilation slowly inflated over 3 minutes, then constant maximal pressure held for 15 seconds.</P>
<P>ES performed with 'cut', 'blended', or 'endocut' mode.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Treatment success.<BR/>(2) Short-term complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published manuscript.</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Iwata-1998">
<CHAR_METHODS>
<P>Randomised clinical trial<BR/>Center type: not described.</P>
<P>Generation of allocation sequence: unclear.<BR/>Allocation concealment: unclear.<BR/>Blinding: unclear.</P>
<P>Length of follow-up: unclear.<BR/>Intention-to-treat: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 78<BR/>Japan</P>
<P>Inclusion and exclusion criteria: not described.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 6 mm to 10 mm.</P>
<P>Time of balloon dilation: not described.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Findings, complications, and prognosis of EBD versus ES.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract.</P>
<P/>
<P/>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lin-2004">
<CHAR_METHODS>
<P>Randomised clinical trial<BR/>Center type: Veterans hospital.</P>
<P>Generation of allocation sequence: unclear.<BR/>Allocation concealment: unclear.<BR/>Blinding: unclear.</P>
<P>Length of follow-up: 16 months.<BR/>Intention-to-treat: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 104<BR/>China</P>
<P>Inclusion criteria: new onset common bile duct stones who underwent endoscopic treatment.</P>
<P>Exclusion criteria: previous sphincterotomy or biliary surgery, stones more than 2.0 cm, bile duct stricture, intrahepatic stones, and pancreatic or biliary malignant disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 8 mm to 12 mm, depending on tolerance of patient.</P>
<P>Dilation time: first 2 patients were for 2 minutes, then subsequent cases increased to 5 min.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Success with stone removal.<BR/>(2) Short-term complications.<BR/>(3) Stone recurrence.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published manuscript.</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Minami-1995">
<CHAR_METHODS>
<P>Randomised clinical trial<BR/>Center type: not described.</P>
<P>Generation of allocation sequence: unclear.<BR/>Allocation concealment: unclear.<BR/>Blinding: not performed.</P>
<P>Length of follow-up: 23 months.<BR/>Intention-to-treat: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 40<BR/>Japan</P>
<P>Inclusion criteria: stones &lt; 12 mm on fluroscopy.</P>
<P>Exclusion criteria: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 8 mm.</P>
<P>Time of dilation: 3 minutes.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Treatment success.<BR/>(2) Pancreatitis rate.<BR/>(3) Papillary function.<BR/>(4) Long-term complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published manuscript.</P>
<P/>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Natsui-2002">
<CHAR_METHODS>
<P>Randomised clinical trial<BR/>Centre type: University/General hospital.</P>
<P>Generation of allocation sequence: <BR/>unclear.<BR/>Allocation concealment: adequate.<BR/>Blinding: unclear.</P>
<P>Length of follow-up: 30 months.<BR/>Intention-to-treat: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 140<BR/>Japan</P>
<P>Inclusion criteria: those with documented common bile ducts stones on ERCP.</P>
<P>Exclusion criteria: patient's history of pancreatitis, cholangitis, cholecystitis, intrahepatic stone disease, pancreatic or biliary malignant disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 8 mm.</P>
<P>Time of dilation: 120 seconds.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Treatment success.<BR/>(2) Complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published manuscript.</P>
<P/>
<P/>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ochi-1999">
<CHAR_METHODS>
<P>Randomised clinical trial<BR/>Center type: not described.</P>
<P>Generation of allocation sequence: unclear.<BR/>Allocation concealment: unclear.<BR/>Blinding: unclear.</P>
<P>Length of follow-up: 23 months.<BR/>Intention-to-treat: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 110<BR/>Japan</P>
<P>Inclusion criteria: stones &lt;15 mm in diameter and &lt; 10 in number as seen on ERCP.</P>
<P>Exclusion criteria: history of recurrent stones following previous sphincterotomy or biliary surgery, intrahepatic stone disease, acute cholangitis, cholecystitis, pancreatitis, or pancreatic or biliary malignant disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 8 mm.</P>
<P>Time of balloon dilation was 60 seconds for three total inflations of 60 seconds each.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Treatment success.<BR/>(2) Short-term complications.<BR/>(3) Long-term complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published manuscript.</P>
<P/>
<P/>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-16 18:00:44 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Tanaka-2004">
<CHAR_METHODS>
<P>Randomised clinical trial<BR/>Center type: not described.</P>
<P>Generation of allocation sequence: unclear.<BR/>Allocation concealment: unclear.<BR/>Blinding: unclear.</P>
<P>Length of follow-up: 60 months.<BR/>Intention-to-treat: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-16 18:00:44 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>N = 32<BR/>Japan</P>
<P>Inclusion criteria: patients with bile duct stones demonstrated on ERCP.</P>
<P>Exclusion criteria: history of liver cirrhosis, haemostatic disorder, gastrectomy with Billroth II anastomosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 8 mm.</P>
<P>Time of balloon dilation was 2 minutes, once.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Treatment success.<BR/>(2) Short-term complications.<BR/>(3) Mid-term complications.<BR/>(4) Long-term complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published manuscript.</P>
<P/>
<P/>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-16 18:00:40 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Vlavianos-2003">
<CHAR_METHODS MODIFIED="2008-10-16 18:00:40 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Randomised clinical trial<BR/>Centre type: single centre (most likely University centre).</P>
<P>Generation of allocation sequence: adequate.<BR/>Allocation concealment: adequate.<BR/>Blinding: not performed.</P>
<P>Length of follow-up: 12 months.<BR/>Intention-to-treat: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 201<BR/>United Kingdom</P>
<P>Inclusion: bile duct stones shown on cholangiogram.</P>
<P>Exclusion: patients with liver parenchyma or bile duct malignancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 10 mm.</P>
<P>Time of balloon dilation: 30 seconds as many times as needed.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Treatment success.<BR/>(2) Short-term complications.<BR/>(3) Long-term complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published manuscript.</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yasuda-2001">
<CHAR_METHODS>
<P>Randomised clinical trial<BR/>Centre type: single center/University.</P>
<P>Generation of allocation sequence: adequate.<BR/>Allocation concealment: adequate.<BR/>Blinding: not performed.</P>
<P>Length of follow-up: 1 year.<BR/>Intention-to-treat: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 70<BR/>Japan</P>
<P>Inclusion criteria: common bile duct stones noted on fluroscopy.</P>
<P>Exclusion criteria: acute pancreatitis, severe cholangitis, coagulopathies, malignant disease, or previous EBD or EST.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EBD versus ES</P>
<P>Balloon diameter: 8 mm.</P>
<P>Time of balloon dilation: 1 minute x 2.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Manometric function.<BR/>(2) Incidence of pneumobilia. <BR/>(3) Long-term complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published manuscript.</P>
<P/>
<P/>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>&lt; : less than.<BR/>&gt; : more than, greater than.<BR/>EBD: endoscopic balloon dilation.<BR/>ES: endoscopic sphincterotomy.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Adamek-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Summary of a randomised clinical trial).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aizawa-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial but no ES arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bergman-1997b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Review article).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bergman-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Review article).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bhasin-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cho-1998b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-DiSario-2003a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Review article).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huibregtse-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Review article).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ido-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kalinsky-1999a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kawabe-1996a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Komatsu-1997a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Komatsu-1998a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Komatsu-1998b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Komatsu-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Komatsu-2001a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mac-Mathuna-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matsumoto-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial but no ES arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moon-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ohashi-1999a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial but no ES arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ohashi-1999b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ohashi-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial but no ES arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Park-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (historical control group).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prat-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial but no ES arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pugliese-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-randomised clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roncoroni-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised clinical trial but no ES arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sato-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sato-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Takahata-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort animal study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wantanbe-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yasuda-1998a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yasuda-1998b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yasuda-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised clinical trial (Cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ES = endoscopic sphincterotomy</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Arnold-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bergman-1997a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bergman-2001a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chen-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cho-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-DiSario-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fujita-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Iwata-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lin-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Minami-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Natsui-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ochi-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tanaka-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Vlavianos-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Yasuda-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-16 17:59:58 +0100" MODIFIED_BY="dimitrinka nikolova">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-16 17:59:58 +0100" MODIFIED_BY="dimitrinka nikolova" NO="1">
<TITLE>Data abstraction form</TITLE>
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Database</P>
</TH>
</TR>
<TR>
<TD>
<P>Attempts will be made to abstract the items listed below from each trial. When possible the total number, percentage, mean, and standard deviation will be recorded for patients within the sphincteroplasty and sphincterotomy groups. <BR/>
<BR/>Abstractor<BR/>Date abstracted<BR/>Study author<BR/>Center<BR/>Study date (Year)<BR/>Total number of patients <BR/>Age<BR/>Gender<BR/>Country of study<BR/>Size of biliary tract stones<BR/>Number of biliary tract stones<BR/>Length of balloon dilation (time)<BR/>Diameter of balloon dilation<BR/>Overall success rate<BR/>Success (removal 1st attempt)<BR/>Treatment failure (repeat procedure)<BR/>Treatment failure (different procedure)<BR/>Overall success rate (stones &lt; 10 mm)<BR/>Success 1st attempt (stones &lt; 10 mm)<BR/>Overall success rate (stones &gt; 10 mm)<BR/>Success 1st attempt (stones &gt; 10 mm)<BR/>Number of balloon dilations<BR/>Demonstration of ductal clearance<BR/>Lithotripsy (0verall)<BR/>Lithotripsy (stones &gt;10 mm)<BR/>Number of procedures required for stone removal<BR/>Preprocedure antibiotics<BR/>Stone recurrence (list time as well)<BR/>Bile duct diameter<BR/>Length of cut<BR/>Duration of procedure<BR/>Length of stay<BR/>Sphincterotomy cut current/type<BR/>Mortality<BR/>Pancreatitis (grade)<BR/>Bleeding<BR/>Perforation<BR/>Infection (cholangitis)<BR/>Infection (non-cholangitis)<BR/>Cholecystitis<BR/>PNA<BR/>Other adverse effects<BR/>Total primary short term adverse events<BR/>Total overall short term adverse events<BR/>Pancreatic duct stenting<BR/>Need for lithotripsy<BR/>Cost<BR/>Length of follow-up<BR/>Use of prophylatic pancreatitis meds (list name)<BR/>Level of endoscopist<BR/>Allocation concealment<BR/>Blinding<BR/>Intention to treat <BR/>Long term complications (LTC) (papillary stenosis)<BR/>LTC (loss sphincter tone more than six months)<BR/>LTC (bacterial contamination of biliary tree)<BR/>LTC (bile duct maligancy)<BR/>LTC (other and list type)<BR/>Total LTC<BR/>Pre-existing coagulopathy (type)<BR/>Abnormal anatomy (list types and numbers)<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Primary outcomes (Technical success)</NAME>
<DICH_OUTCOME CHI2="5.419347077440528" CI_END="0.9726994127517639" CI_START="0.8418807147234517" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9049292109433404" ESTIMABLE="YES" EVENTS_1="285" EVENTS_2="322" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.012021346321233738" LOG_CI_START="-0.07474943891282082" LOG_EFFECT_SIZE="-0.04338539261702727" METHOD="MH" NO="1" P_CHI2="0.49125799111684465" P_Q="0.0" P_Z="0.006704272440333516" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="388" TOTAL_2="398" WEIGHT="100.0" Z="2.7111873953555534">
<NAME>Stone removal on 1st attempt</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.333588033402274" CI_START="0.7128325811193343" EFFECT_SIZE="0.975" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.1250216898113432" LOG_CI_START="-0.14701245841426955" LOG_EFFECT_SIZE="-0.010995384301463193" ORDER="448" O_E="0.0" SE="0.1597942052584762" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="0.025534188034188027" WEIGHT="5.317130452899359"/>
<DICH_DATA CI_END="1.0674404974600207" CI_START="0.7499753087178354" EFFECT_SIZE="0.8947368421052632" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.028343675411341394" LOG_CI_START="-0.12495303456045138" LOG_EFFECT_SIZE="-0.04830467957455503" ORDER="449" O_E="0.0" SE="0.09004724626838372" STUDY_ID="STD-Cho-1998" TOTAL_1="42" TOTAL_2="42" VAR="0.008108506560518945" WEIGHT="16.743972243632292"/>
<DICH_DATA CI_END="1.100635919862053" CI_START="0.8541710350589903" EFFECT_SIZE="0.9696036937283571" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="113" LOG_CI_END="0.04164368214706535" LOG_CI_START="-0.06845515958600233" LOG_EFFECT_SIZE="-0.013405738719468494" ORDER="450" O_E="0.0" SE="0.06467260463206016" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="0.0041825457898947704" WEIGHT="32.46075849657474"/>
<DICH_DATA CI_END="1.0704681341027238" CI_START="0.7677319964760518" EFFECT_SIZE="0.9065498539841469" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="47" LOG_CI_END="0.029573743662844224" LOG_CI_START="-0.11479035908910272" LOG_EFFECT_SIZE="-0.04260830771312927" ORDER="451" O_E="0.0" SE="0.0848001885703274" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="53" VAR="0.0071910719815630846" WEIGHT="18.88016267042404"/>
<DICH_DATA CI_END="1.0740344708590832" CI_START="0.6518645042913318" EFFECT_SIZE="0.8367346938775511" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="0.03101822015650375" LOG_CI_START="-0.18584266677406003" LOG_EFFECT_SIZE="-0.07741222330877814" ORDER="452" O_E="0.0" SE="0.12738515846171633" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="0.016226978596316582" WEIGHT="8.366844633507938"/>
<DICH_DATA CI_END="0.937080465671295" CI_START="0.656451652261941" EFFECT_SIZE="0.7843137254901961" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="51" LOG_CI_END="-0.028223115305805575" LOG_CI_START="-0.18279725423414234" LOG_EFFECT_SIZE="-0.10551018476997398" ORDER="453" O_E="0.0" SE="0.09079761436083297" STUDY_ID="STD-Ochi-1999" TOTAL_1="55" TOTAL_2="55" VAR="0.008244206773618541" WEIGHT="16.468365303633462"/>
<DICH_DATA CI_END="2.105620019898895" CI_START="0.7094476431533719" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.32338000115607135" LOG_CI_START="-0.149079649718271" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="454" O_E="0.0" SE="0.2775251376365788" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.07702020202020202" WEIGHT="1.762766199328173"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0088255053185302" CI_END="1.6362017422729835" CI_START="0.5733059139935444" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9685267860682235" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.21383685077432613" LOG_CI_START="-0.24161357819477364" LOG_EFFECT_SIZE="-0.013888363710223799" METHOD="MH" NO="2" P_CHI2="0.9852755514562894" P_Q="0.0" P_Z="0.9048530464116683" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="437" TOTAL_2="438" WEIGHT="100.0" Z="0.11953306417054017">
<NAME>Stone recurrence overall</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.033430421473012" CI_START="0.4305760368636865" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4819340378767768" LOG_CI_START="-0.3659501439214033" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="455" O_E="0.0" SE="0.4980513654826408" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="0.24805516265912303" WEIGHT="27.580626723684887"/>
<DICH_DATA CI_END="70.30165551536152" CI_START="0.12274115291800639" EFFECT_SIZE="2.9375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469655522277983" LOG_CI_START="-0.9110098016682132" LOG_EFFECT_SIZE="0.4679778752797927" ORDER="456" O_E="0.0" SE="1.6200483750766987" STUDY_ID="STD-Chen-1998" TOTAL_1="47" TOTAL_2="46" VAR="2.624556737588652" WEIGHT="1.9907820793035709"/>
<DICH_DATA CI_END="3.3118971842772984" CI_START="0.1834243834156038" EFFECT_SIZE="0.7794117647058824" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5200768459286288" LOG_CI_START="-0.7365429321395233" LOG_EFFECT_SIZE="-0.10823304310544726" ORDER="457" O_E="0.0" SE="0.7381446780054547" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="53" VAR="0.5448575656677764" WEIGHT="15.457274317669553"/>
<DICH_DATA CI_END="4.852360598675257" CI_START="0.21219116072345484" EFFECT_SIZE="1.0147058823529411" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6859530675852374" LOG_CI_START="-0.6732727115231993" LOG_EFFECT_SIZE="0.006340178031018974" ORDER="458" O_E="0.0" SE="0.7984159509244145" STUDY_ID="STD-Natsui-2002" TOTAL_1="68" TOTAL_2="69" VAR="0.6374680306905371" WEIGHT="11.73398926304842"/>
<DICH_DATA CI_END="4.05308776088479" CI_START="0.12293587644522143" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.607786007555004" LOG_CI_START="-0.9103213582163021" LOG_EFFECT_SIZE="-0.15126767533064905" ORDER="459" O_E="0.0" SE="0.8917437814067222" STUDY_ID="STD-Ochi-1999" TOTAL_1="51" TOTAL_2="54" VAR="0.7952069716775598" WEIGHT="11.482546635983097"/>
<DICH_DATA CI_END="2.794948790292304" CI_START="0.3577883084918408" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4463738550499143" LOG_CI_START="-0.4463738550499143" LOG_EFFECT_SIZE="0.0" ORDER="460" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.275" WEIGHT="19.70044765977492"/>
<DICH_DATA CI_END="3.7536394857318434" CI_START="0.1093857786767741" EFFECT_SIZE="0.6407766990291263" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.574452558941738" LOG_CI_START="-0.9610391372683449" LOG_EFFECT_SIZE="-0.1932932891633035" ORDER="461" O_E="0.0" SE="0.9019554231602832" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="0.8135235853682455" WEIGHT="12.054333320535545"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Primary adverse event outcomes</NAME>
<DICH_OUTCOME CHI2="1.76184366644222" CI_END="6.055054481833071" CI_START="0.4285274469968042" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6108249558926266" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.7821180551674307" LOG_CI_START="-0.36802135647704726" LOG_EFFECT_SIZE="0.2070483493451917" METHOD="MH" NO="1" P_CHI2="0.6232732875281737" P_Q="0.0" P_Z="0.4803956921279554" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="595" TOTAL_2="602" WEIGHT="100.0" Z="0.7056662934362309">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.77928894591074" CI_START="0.12366155441129352" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8620078082112523" LOG_CI_START="-0.9077652987719278" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="462" O_E="0.0" SE="1.6269784336399213" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="2.6470588235294117" WEIGHT="14.432879826649142"/>
<DICH_DATA CI_END="16.55254127889542" CI_START="0.0764610689485897" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2188646796026918" LOG_CI_START="-1.1165596347079294" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="463" O_E="0.0" SE="1.3718398027628607" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="1.8819444444444444" WEIGHT="27.16777379133956"/>
<DICH_DATA CI_END="105.66775087315581" CI_START="0.24877358866001678" EFFECT_SIZE="5.127118644067797" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0239424636098855" LOG_CI_START="-0.6041957289171985" LOG_EFFECT_SIZE="0.7098733673463435" ORDER="464" O_E="0.0" SE="1.5437813837842767" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="2.383260960918896" WEIGHT="14.25171397108451"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="465" O_E="0.0" SE="0.0" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="466" O_E="0.0" SE="0.0" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="467" O_E="0.0" SE="0.0" STUDY_ID="STD-Ochi-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.775529738050333" CI_START="0.013211764545169381" EFFECT_SIZE="0.32051282051282054" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8907299866988743" LOG_CI_START="-1.8790391747357595" LOG_EFFECT_SIZE="-0.49415459401844275" ORDER="468" O_E="0.0" SE="1.6269761160051743" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="2.647051282051282" WEIGHT="44.14763241092678"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.431064199656863" CI_END="2.904745272563715" CI_START="1.3472719326795133" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9782522026548073" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="36" I2="20.881570164691553" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.46310805356956763" LOG_CI_START="0.12945526234722673" LOG_EFFECT_SIZE="0.2962816579583972" METHOD="MH" NO="2" P_CHI2="0.22663382072012417" P_Q="0.0" P_Z="4.997837158034913E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="827" TOTAL_2="837" WEIGHT="100.00000000000001" Z="3.480872296922003">
<NAME>Total pancreatitis</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.267071756978603" CI_START="0.5504280312298803" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.861359448552416" LOG_CI_START="-0.2592994572244536" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="469" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Arnold-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.43333333333333335" WEIGHT="8.174412741737394"/>
<DICH_DATA CI_END="2.747491913706595" CI_START="0.3639683141599922" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.43893642290161633" LOG_CI_START="-0.4389364229016163" LOG_EFFECT_SIZE="0.0" ORDER="470" O_E="0.0" SE="0.5156668551654895" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="0.2659123055162659" WEIGHT="19.073629730720583"/>
<DICH_DATA CI_END="76.92616453299082" CI_START="0.1461429229069466" EFFECT_SIZE="3.3529411764705883" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8860740794586417" LOG_CI_START="-0.835222210870207" LOG_EFFECT_SIZE="0.5254259342942175" ORDER="471" O_E="0.0" SE="1.5985029115730547" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="2.5552115583075334" WEIGHT="1.2867131167549601"/>
<DICH_DATA CI_END="27.20691780840997" CI_START="0.3168714508215705" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4346793446236137" LOG_CI_START="-0.49911688769257545" LOG_EFFECT_SIZE="0.46778122846551906" ORDER="472" O_E="0.0" SE="1.1359214793082617" STUDY_ID="STD-Chen-1998" TOTAL_1="47" TOTAL_2="46" VAR="1.2903176071538698" WEIGHT="2.75410321764629"/>
<DICH_DATA CI_END="4.6743560803370325" CI_START="0.2139332097968663" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6697217927449455" LOG_CI_START="-0.6697217927449455" LOG_EFFECT_SIZE="0.0" ORDER="473" O_E="0.0" SE="0.7867957924694431" STUDY_ID="STD-Cho-1998" TOTAL_1="42" TOTAL_2="42" VAR="0.619047619047619" WEIGHT="8.174412741737394"/>
<DICH_DATA CI_END="136.07347885731704" CI_START="2.5047379197547186" EFFECT_SIZE="18.46153846153846" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" LOG_CI_END="2.1337734881108026" LOG_CI_START="0.39876229069873614" LOG_EFFECT_SIZE="1.2662678894047692" ORDER="474" O_E="0.0" SE="1.0191541658037875" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="1.0386752136752138" WEIGHT="2.6903130542426865"/>
<DICH_DATA CI_END="11.498914122071845" CI_START="1.3315961055287076" EFFECT_SIZE="3.9130434782608696" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0606568305224462" LOG_CI_START="0.12437251632101791" LOG_EFFECT_SIZE="0.5925146734217319" ORDER="475" O_E="0.0" SE="0.5499780408440214" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="0.30247584541062805" WEIGHT="10.667318755175039"/>
<DICH_DATA CI_END="2.850999397756464" CI_START="0.10767308300917255" EFFECT_SIZE="0.5540540540540541" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4549971255693435" LOG_CI_START="-0.9678928515918248" LOG_EFFECT_SIZE="-0.2564478630112407" ORDER="476" O_E="0.0" SE="0.835812616003452" STUDY_ID="STD-Iwata-1998" TOTAL_1="37" TOTAL_2="41" VAR="0.698582729070534" WEIGHT="10.34028278441995"/>
<DICH_DATA CI_END="6.41978801003991" CI_START="0.15576838338526122" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8075206873227565" LOG_CI_START="-0.8075206873227565" LOG_EFFECT_SIZE="0.0" ORDER="477" O_E="0.0" SE="0.9486832980505138" STUDY_ID="STD-Minami-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.8999999999999999" WEIGHT="5.449608494491596"/>
<DICH_DATA CI_END="5.74028649588045" CI_START="0.30970192499165505" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7589335684389047" LOG_CI_START="-0.5090560952223049" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="478" O_E="0.0" SE="0.7448234050846582" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="0.5547619047619048" WEIGHT="8.174412741737394"/>
<DICH_DATA CI_END="4.072465416765633" CI_START="0.00982206008068895" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6098574049826039" LOG_CI_START="-2.0077974136546413" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="479" O_E="0.0" SE="1.5376233980678475" STUDY_ID="STD-Ochi-1999" TOTAL_1="55" TOTAL_2="55" VAR="2.3642857142857143" WEIGHT="6.812010618114495"/>
<DICH_DATA CI_END="4.231237209631626" CI_START="0.23633749432049936" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6264673732269029" LOG_CI_START="-0.6264673732269029" LOG_EFFECT_SIZE="0.0" ORDER="480" O_E="0.0" SE="0.7359800721939872" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.5416666666666666" WEIGHT="8.174412741737394"/>
<DICH_DATA CI_END="40.40955456380315" CI_START="0.5715469153980235" EFFECT_SIZE="4.805825242718447" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6064840632229367" LOG_CI_START="-0.24294811476614378" LOG_EFFECT_SIZE="0.6817679742283965" ORDER="481" O_E="0.0" SE="1.0863656161877142" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="1.1801902520349121" WEIGHT="2.7787607669932393"/>
<DICH_DATA CI_END="6.706930006003608" CI_START="0.1490995133548233" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8265237740363401" LOG_CI_START="-0.82652377403634" LOG_EFFECT_SIZE="0.0" ORDER="482" O_E="0.0" SE="0.9710083124552245" STUDY_ID="STD-Yasuda-2001" TOTAL_1="35" TOTAL_2="35" VAR="0.9428571428571428" WEIGHT="5.449608494491596"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9455512637607568" CI_END="0.38552869143635027" CI_START="0.059570815252785445" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1515462254633976" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.41394329577434574" LOG_CI_START="-1.2249664563496472" LOG_EFFECT_SIZE="-0.8194548760619966" METHOD="MH" NO="3" P_CHI2="0.998569526964896" P_Q="0.0" P_Z="7.473629337066707E-5" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="673" TOTAL_2="690" WEIGHT="100.00000000000003" Z="3.960681080668409">
<NAME>Bleeding</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9981665126016623" CI_START="0.010004585820506876" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6018608773254142" LOG_CI_START="-1.9998008859974516" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="483" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Arnold-2001" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="9.717730371406983"/>
<DICH_DATA CI_END="2.0372454527823454" CI_START="0.006059986044138521" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.30904335711358033" LOG_CI_START="-2.2175283759922304" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="484" O_E="0.0" SE="1.484120742758138" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="2.2026143790849675" WEIGHT="10.303938247358039"/>
<DICH_DATA CI_END="2.8729942414780383" CI_START="0.008873164308204829" EFFECT_SIZE="0.15966386554621848" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4583347555092401" LOG_CI_START="-2.0519214763886438" LOG_EFFECT_SIZE="-0.7967933604397018" ORDER="485" O_E="0.0" SE="1.4745369365855683" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="2.1742591773551525" WEIGHT="10.438315165555435"/>
<DICH_DATA CI_END="4.044504981919023" CI_START="0.00988996185659807" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6068653747055984" LOG_CI_START="-2.004805383377636" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="486" O_E="0.0" SE="1.534108331276844" STUDY_ID="STD-Cho-1998" TOTAL_1="42" TOTAL_2="42" VAR="2.353488372093023" WEIGHT="9.6433884330818"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="487" O_E="0.0" SE="0.0" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.307072456717163" CI_START="0.010106114571163536" EFFECT_SIZE="0.20863309352517986" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6341821778428773" LOG_CI_START="-1.9954157825531553" LOG_EFFECT_SIZE="-0.680616802355139" ORDER="488" O_E="0.0" SE="1.5446388586564646" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="2.3859092036715457" WEIGHT="9.512349635899533"/>
<DICH_DATA CI_END="2.9585199623852754" CI_START="0.008426763462612409" EFFECT_SIZE="0.15789473684210525" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.47107450399143935" LOG_CI_START="-2.0743391964577724" LOG_EFFECT_SIZE="-0.8016323462331666" ORDER="489" O_E="0.0" SE="1.4951886076448944" STUDY_ID="STD-Iwata-1998" TOTAL_1="37" TOTAL_2="41" VAR="2.235588972431078" WEIGHT="10.151956743709544"/>
<DICH_DATA CI_END="0.544114458630633" CI_START="0.010126632491965794" EFFECT_SIZE="0.0742296918767507" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.26430973353157056" LOG_CI_START="-1.9945349508192003" LOG_EFFECT_SIZE="-1.1294223421753853" ORDER="490" O_E="0.0" SE="1.0163428573877098" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="53" VAR="1.0329528037630147" WEIGHT="21.971577464289755"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="491" O_E="0.0" SE="0.0" STUDY_ID="STD-Minami-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.092080860459946" CI_START="0.009774977905862802" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.611944206883865" LOG_CI_START="-2.0098842155559025" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="492" O_E="0.0" SE="1.540074993601121" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="2.371830985915493" WEIGHT="9.56881104918789"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="493" O_E="0.0" SE="0.0" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="494" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-Yasuda-2001" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="8.691932889511037"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0697045700322911" CI_END="3.4625687359110353" CI_START="0.17498489850652113" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.778394012583117" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.5393984033954147" LOG_CI_START="-0.7569994300467505" LOG_EFFECT_SIZE="-0.10880051332566788" METHOD="MH" NO="4" P_CHI2="0.5857559120608373" P_Q="0.0" P_Z="0.7421700966604177" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="586" TOTAL_2="599" WEIGHT="100.0" Z="0.32898093797576927">
<NAME>Perforation</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.70854116808942" CI_START="0.18425927237707806" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3366306394868346" LOG_CI_START="-0.7345706481588722" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="495" O_E="0.0" SE="1.216633888974814" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="1.4801980198019802" WEIGHT="25.655246444225778"/>
<DICH_DATA CI_END="8.54735161477676" CI_START="0.016238102545216286" EFFECT_SIZE="0.37254901960784315" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.931831570019317" LOG_CI_START="-1.789464720309532" LOG_EFFECT_SIZE="-0.4288165751451074" ORDER="496" O_E="0.0" SE="1.5985029115730547" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="2.5552115583075334" WEIGHT="36.34493246265319"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="497" O_E="0.0" SE="0.0" STUDY_ID="STD-Cho-1998" TOTAL_1="42" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.306516041326866" CI_START="0.014065180454349548" EFFECT_SIZE="0.3418079096045198" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9194189081053092" LOG_CI_START="-1.8518546915239846" LOG_EFFECT_SIZE="-0.4662178917093377" ORDER="498" O_E="0.0" SE="1.627859830447807" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="2.6499276275855626" WEIGHT="37.99982109312103"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="499" O_E="0.0" SE="0.0" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="500" O_E="0.0" SE="0.0" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="501" O_E="0.0" SE="0.0" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="502" O_E="0.0" SE="0.0" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="503" O_E="0.0" SE="0.0" STUDY_ID="STD-Yasuda-2001" TOTAL_1="35" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.814203109204337" CI_END="1.8908224988466855" CI_START="0.3921823644824468" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8611313711706836" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.2766507613201249" LOG_CI_START="-0.40651193942947916" LOG_EFFECT_SIZE="-0.06493058905467713" METHOD="MH" NO="5" P_CHI2="0.43897359118290546" P_Q="0.0" P_Z="0.709471441966174" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="481" TOTAL_2="486" WEIGHT="100.0" Z="0.3725660546235891">
<NAME>Cholangitis</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.814203109204337" CI_END="1.8908224988466855" CI_START="0.3921823644824468" DF="5.0" EFFECT_SIZE="0.8611313711706836" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.2766507613201249" LOG_CI_START="-0.40651193942947916" LOG_EFFECT_SIZE="-0.06493058905467713" NO="1" P_CHI2="0.43897359118290546" P_Z="0.709471441966174" STUDIES="7" TAU2="0.0" TOTAL_1="481" TOTAL_2="486" WEIGHT="100.0" Z="0.3725660546235891">
<NAME>Cholangitis</NAME>
<DICH_DATA CI_END="157.13841454196506" CI_START="0.3835729777627365" EFFECT_SIZE="7.763636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1962823669891645" LOG_CI_START="-0.41615199592760443" LOG_EFFECT_SIZE="0.89006518553078" ORDER="504" O_E="0.0" SE="1.5345568765359672" STUDY_ID="STD-Arnold-2001" TOTAL_1="30" TOTAL_2="30" VAR="2.354864807323824" WEIGHT="3.304669011081367"/>
<DICH_DATA CI_END="5.263066454764843" CI_START="0.1900033010403401" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7212388537253259" LOG_CI_START="-0.7212388537253259" LOG_EFFECT_SIZE="0.0" ORDER="505" O_E="0.0" SE="0.8473185457363234" STUDY_ID="STD-Cho-1998" TOTAL_1="42" TOTAL_2="42" VAR="0.717948717948718" WEIGHT="20.755038100765574"/>
<DICH_DATA CI_END="16.595188466062556" CI_START="0.06341554883178176" EFFECT_SIZE="1.0258620689655173" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.219982188911313" LOG_CI_START="-1.1978042445800883" LOG_EFFECT_SIZE="0.011088972165612327" ORDER="506" O_E="0.0" SE="1.420219719268716" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="2.0170240509997104" WEIGHT="7.2933423943834885"/>
<DICH_DATA CI_END="1.705260724948645" CI_START="0.06708834169056266" EFFECT_SIZE="0.3382352941176471" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2317907896333971" LOG_CI_START="-1.1733529430106837" LOG_EFFECT_SIZE="-0.47078107668864344" ORDER="507" O_E="0.0" SE="0.8253883841287878" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="0.6812659846547314" WEIGHT="43.117940582496075"/>
<DICH_DATA CI_END="3.969340472777186" CI_START="0.007782332014105859" EFFECT_SIZE="0.17575757575757575" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5987183523983605" LOG_CI_START="-2.108890245028261" LOG_EFFECT_SIZE="-0.7550859463149502" ORDER="508" O_E="0.0" SE="1.5904626930071135" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="2.52957157784744" WEIGHT="18.078483413562772"/>
<DICH_DATA CI_END="21.74716807640006" CI_START="0.17316761843066703" EFFECT_SIZE="1.9405940594059405" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3374027109979014" LOG_CI_START="-0.7615333158502342" LOG_EFFECT_SIZE="0.2879346975738335" ORDER="509" O_E="0.0" SE="1.2329254120714939" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="1.5201050717316629" WEIGHT="7.450526497710719"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="510" O_E="0.0" SE="0.0" STUDY_ID="STD-Yasuda-2001" TOTAL_1="35" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.539610631930427" CI_END="0.6781519740676273" CI_START="0.12042730159887748" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.2857761577019963" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-0.16867296969793336" LOG_CI_START="-0.9192750447258795" LOG_EFFECT_SIZE="-0.5439740072119065" METHOD="MH" NO="6" P_CHI2="0.9084540267893386" P_Q="0.0" P_Z="0.004499515783073759" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="518" TOTAL_2="531" WEIGHT="100.0" Z="2.8408380369094317">
<NAME>Cholecystitis</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.539610631930427" CI_END="0.6781519740676273" CI_START="0.12042730159887748" DF="5.0" EFFECT_SIZE="0.2857761577019963" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="25" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-0.16867296969793336" LOG_CI_START="-0.9192750447258795" LOG_EFFECT_SIZE="-0.5439740072119065" NO="1" P_CHI2="0.9084540267893386" P_Z="0.004499515783073759" STUDIES="6" TAU2="0.0" TOTAL_1="518" TOTAL_2="531" WEIGHT="100.0" Z="2.8408380369094317">
<NAME>Cholecystitis</NAME>
<DICH_DATA CI_END="1.1121981112376143" CI_START="0.016213526060710883" EFFECT_SIZE="0.13428571428571429" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.046182153211859533" LOG_CI_START="-1.790122526040976" LOG_EFFECT_SIZE="-0.8719701864145581" ORDER="511" O_E="0.0" SE="1.0786544584478772" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="1.1634954407294833" WEIGHT="16.708214403372"/>
<DICH_DATA CI_END="8.406345038799735" CI_START="0.01367131708614078" EFFECT_SIZE="0.33900709219858155" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.924607211671257" LOG_CI_START="-1.864189643757779" LOG_EFFECT_SIZE="-0.469791216043261" ORDER="512" O_E="0.0" SE="1.6381530776460906" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="2.6835455058013586" WEIGHT="7.244122091102334"/>
<DICH_DATA CI_END="2.0852685074847854" CI_START="0.1252762255621129" EFFECT_SIZE="0.5111111111111111" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.31916198439898524" LOG_CI_START="-0.902131339914487" LOG_EFFECT_SIZE="-0.29148467775775083" ORDER="513" O_E="0.0" SE="0.7173937442011895" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="0.5146537842190017" WEIGHT="37.77283268314937"/>
<DICH_DATA CI_END="2.9373901930264825" CI_START="0.007323205191526685" EFFECT_SIZE="0.14666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4679616405720409" LOG_CI_START="-2.135298797038991" LOG_EFFECT_SIZE="-0.8336685782334751" ORDER="514" O_E="0.0" SE="1.5291680673997146" STUDY_ID="STD-Iwata-1998" TOTAL_1="37" TOTAL_2="41" VAR="2.338354978354978" WEIGHT="8.313507342127288"/>
<DICH_DATA CI_END="3.189856487989341" CI_START="0.03284261807485103" EFFECT_SIZE="0.32367149758454106" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5037711445379547" LOG_CI_START="-1.4835622300501372" LOG_EFFECT_SIZE="-0.4898955427560913" ORDER="515" O_E="0.0" SE="1.167369461691906" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="1.3627514600908501" WEIGHT="14.265206716240108"/>
<DICH_DATA CI_END="1.6402036392361539" CI_START="0.020908106769011874" EFFECT_SIZE="0.18518518518518517" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.21489777116126094" LOG_CI_START="-1.6796852908071978" LOG_EFFECT_SIZE="-0.7323937598229685" ORDER="516" O_E="0.0" SE="1.1128874689376813" STUDY_ID="STD-Ochi-1999" TOTAL_1="55" TOTAL_2="55" VAR="1.2385185185185186" WEIGHT="15.696116764008917"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.213043515570899" CI_START="0.1417688353226731" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.9644031224519625" LOG_CI_START="-0.848419228496589" LOG_EFFECT_SIZE="0.05799194697768673" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.9002084898487814" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="88" WEIGHT="100.0" Z="0.12539797670758995">
<NAME>Nonbiliar infection</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.213043515570899" CI_START="0.1417688353226731" DF="0.0" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="0.9644031224519625" LOG_CI_START="-0.848419228496589" LOG_EFFECT_SIZE="0.05799194697768673" NO="1" P_CHI2="1.0" P_Z="0.9002084898487814" STUDIES="2" TAU2="0.0" TOTAL_1="86" TOTAL_2="88" WEIGHT="100.0" Z="0.12539797670758995">
<NAME>Non biliary</NAME>
<DICH_DATA CI_END="9.213043515570899" CI_START="0.1417688353226731" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9644031224519625" LOG_CI_START="-0.848419228496589" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="517" O_E="0.0" SE="1.0648608225625409" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="1.1339285714285714" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="518" O_E="0.0" SE="0.0" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.19046449249582" CI_END="0.9617515121183614" CI_START="0.3123482442011773" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.548088857912654" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-0.016937122199057904" LOG_CI_START="-0.5053609310046034" LOG_EFFECT_SIZE="-0.26114902660183065" METHOD="MH" NO="8" P_CHI2="0.5141284575516111" P_Q="0.0" P_Z="0.03609144192645037" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="786" TOTAL_2="795" WEIGHT="100.00000000000001" Z="2.0958957262505558">
<NAME>Total Infections</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="129.92776744614594" CI_START="0.3771326250203609" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1137019760147355" LOG_CI_START="-0.423505895986222" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="519" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Arnold-2001" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="3.7057963705361168"/>
<DICH_DATA CI_END="1.0717416459700249" CI_START="0.017065066448056682" EFFECT_SIZE="0.13523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.030090106949864078" LOG_CI_START="-1.7678920163236274" LOG_EFFECT_SIZE="-0.8689009546868816" ORDER="520" O_E="0.0" SE="1.0561435993658987" STUDY_ID="STD-Bergman-1997a" TOTAL_1="75" TOTAL_2="71" VAR="1.1154393024815559" WEIGHT="7.379431627486407"/>
<DICH_DATA CI_END="7.088135988724078" CI_START="0.17855540610583326" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8505320410722685" LOG_CI_START="-0.7482269961775061" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="521" O_E="0.0" SE="0.9391189724653871" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="0.8819444444444444" WEIGHT="9.33313670620018"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="522" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-1998" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.6743560803370325" CI_START="0.2139332097968663" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6697217927449455" LOG_CI_START="-0.6697217927449455" LOG_EFFECT_SIZE="0.0" ORDER="523" O_E="0.0" SE="0.7867957924694431" STUDY_ID="STD-Cho-1998" TOTAL_1="42" TOTAL_2="42" VAR="0.619047619047619" WEIGHT="13.296728416365324"/>
<DICH_DATA CI_END="5.5794009380331016" CI_START="0.04713496687015352" EFFECT_SIZE="0.5128205128205128" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7465875711108277" LOG_CI_START="-1.3266567938358638" LOG_EFFECT_SIZE="-0.29003461136251807" ORDER="524" O_E="0.0" SE="1.2178340026948082" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="1.4831196581196582" WEIGHT="5.549995930678756"/>
<DICH_DATA CI_END="1.2018950864860032" CI_START="0.15728154557722956" EFFECT_SIZE="0.43478260869565216" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.07986655972265862" LOG_CI_START="-0.8033222317578445" LOG_EFFECT_SIZE="-0.3617278360175929" ORDER="525" O_E="0.0" SE="0.5187894679706737" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="0.2691425120772947" WEIGHT="30.583455596601663"/>
<DICH_DATA CI_END="2.9585199623852754" CI_START="0.008426763462612409" EFFECT_SIZE="0.15789473684210525" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.47107450399143935" LOG_CI_START="-2.0743391964577724" LOG_EFFECT_SIZE="-0.8016323462331666" ORDER="526" O_E="0.0" SE="1.4951886076448944" STUDY_ID="STD-Iwata-1998" TOTAL_1="37" TOTAL_2="41" VAR="2.235588972431078" WEIGHT="3.681941613051832"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="527" O_E="0.0" SE="0.0" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.8682013368369814" CI_START="0.11489692643761545" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5875090706854438" LOG_CI_START="-0.9396915887968063" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="528" O_E="0.0" SE="0.8970852271450604" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="0.8047619047619048" WEIGHT="10.228252627973324"/>
<DICH_DATA CI_END="1.656677359194248" CI_START="0.02414471337946856" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.21923793704630978" LOG_CI_START="-1.6171779457183475" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="529" O_E="0.0" SE="1.0787197799411874" STUDY_ID="STD-Ochi-1999" TOTAL_1="55" TOTAL_2="55" VAR="1.1636363636363638" WEIGHT="7.073780370313396"/>
<DICH_DATA CI_END="3.8634844753344426" CI_START="0.010353348190052555" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5869791714561268" LOG_CI_START="-1.9849191801281645" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="530" O_E="0.0" SE="1.5107458228227775" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="2.282352941176471" WEIGHT="3.606500957310672"/>
<DICH_DATA CI_END="20.865360474038877" CI_START="0.17710468059086762" EFFECT_SIZE="1.9223300970873787" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3194258920687503" LOG_CI_START="-0.7517699609560325" LOG_EFFECT_SIZE="0.28382796555635886" ORDER="531" O_E="0.0" SE="1.2166306966515814" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="1.4801902520349122" WEIGHT="5.5609797834823365"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="532" O_E="0.0" SE="0.0" STUDY_ID="STD-Yasuda-2001" TOTAL_1="35" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.02596776625824" CI_END="1.62913849168701" CI_START="0.6238402717818576" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0081280669757735" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="88" I2="53.37369270164695" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.21195800488487382" LOG_CI_START="-0.20492659295158938" LOG_EFFECT_SIZE="0.0035157059666421657" METHOD="MH" NO="9" P_CHI2="0.007569317152994914" P_Q="0.0" P_Z="0.9736284443863197" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.44287225979183786" TOTALS="YES" TOTAL_1="878" TOTAL_2="890" WEIGHT="100.00000000000003" Z="0.03305786354598952">
<NAME>Total primary short-term complications</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.7437065088708765" CI_START="0.683010214468602" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6761178115702067" LOG_CI_START="-0.16557280136359445" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="533" O_E="0.0" SE="0.4944132324730442" STUDY_ID="STD-Arnold-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.24444444444444446" WEIGHT="8.724690006637363"/>
<DICH_DATA CI_END="2.6432349621998563" CI_START="0.2627252039169786" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.42213577011291736" LOG_CI_START="-0.5804982622081669" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="534" O_E="0.0" SE="0.588952193703909" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="0.3468646864686469" WEIGHT="7.593193162913401"/>
<DICH_DATA CI_END="2.0070307307668003" CI_START="0.10089531609844032" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3025540222634048" LOG_CI_START="-0.9961289947127174" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="535" O_E="0.0" SE="0.7628528327563872" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="0.5819444444444444" WEIGHT="5.851412409708963"/>
<DICH_DATA CI_END="27.20691780840997" CI_START="0.3168714508215705" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4346793446236137" LOG_CI_START="-0.49911688769257545" LOG_EFFECT_SIZE="0.46778122846551906" ORDER="536" O_E="0.0" SE="1.1359214793082617" STUDY_ID="STD-Chen-1998" TOTAL_1="47" TOTAL_2="46" VAR="1.2903176071538698" WEIGHT="3.459877821356468"/>
<DICH_DATA CI_END="1.974989703942113" CI_START="0.2848116113604241" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.295564835895248" LOG_CI_START="-0.5454423091118479" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="537" O_E="0.0" SE="0.4940117600296768" STUDY_ID="STD-Cho-1998" TOTAL_1="42" TOTAL_2="42" VAR="0.24404761904761899" WEIGHT="8.729730155686351"/>
<DICH_DATA CI_END="23.425812693425108" CI_START="2.2003521002662105" EFFECT_SIZE="7.17948717948718" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="3" LOG_CI_END="1.3696946664604628" LOG_CI_START="0.3424921821709774" LOG_EFFECT_SIZE="0.8560934243157201" ORDER="538" O_E="0.0" SE="0.6033838240059465" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="0.364072039072039" WEIGHT="7.431275230877849"/>
<DICH_DATA CI_END="2.9802026992964636" CI_START="0.7332572375038736" EFFECT_SIZE="1.4782608695652173" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" LOG_CI_END="0.474245803738047" LOG_CI_START="-0.13474364168872258" LOG_EFFECT_SIZE="0.16975108102466221" ORDER="539" O_E="0.0" SE="0.3577234147900573" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="0.12796604148905938" WEIGHT="10.504945388894656"/>
<DICH_DATA CI_END="0.9463814519109611" CI_START="0.05189888608976906" EFFECT_SIZE="0.22162162162162163" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.023933780015435616" LOG_CI_START="-1.284841963351121" LOG_EFFECT_SIZE="-0.6543878716832783" ORDER="540" O_E="0.0" SE="0.7406637084875523" STUDY_ID="STD-Iwata-1998" TOTAL_1="37" TOTAL_2="41" VAR="0.5485827290705338" WEIGHT="6.048308040414368"/>
<DICH_DATA CI_END="0.544114458630633" CI_START="0.010126632491965794" EFFECT_SIZE="0.0742296918767507" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.26430973353157056" LOG_CI_START="-1.9945349508192003" LOG_EFFECT_SIZE="-1.1294223421753853" ORDER="541" O_E="0.0" SE="1.0163428573877098" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="53" VAR="1.0329528037630147" WEIGHT="4.063235764814169"/>
<DICH_DATA CI_END="6.908394353638776" CI_START="0.5790057421798926" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8393771205458188" LOG_CI_START="-0.23731712921785644" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="542" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Minami-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.4" WEIGHT="7.114512443826532"/>
<DICH_DATA CI_END="2.2823851969871054" CI_START="0.33544951176982485" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.35838894192641935" LOG_CI_START="-0.4743728358817928" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="543" O_E="0.0" SE="0.4891683905218266" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="0.23928571428571427" WEIGHT="8.7906693298633"/>
<DICH_DATA CI_END="3.106461858025365" CI_START="0.035767737119984905" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4922660255973533" LOG_CI_START="-1.4465085350366782" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="544" O_E="0.0" SE="1.138845774005285" STUDY_ID="STD-Ochi-1999" TOTAL_1="55" TOTAL_2="55" VAR="1.296969696969697" WEIGHT="3.4466493680880492"/>
<DICH_DATA CI_END="2.827010570207606" CI_START="0.19897343360788772" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4513274323219404" LOG_CI_START="-0.7012049055385404" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="545" O_E="0.0" SE="0.67700320038633" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.45833333333333326" WEIGHT="6.654003511063798"/>
<DICH_DATA CI_END="8.429699648808084" CI_START="0.5966744060020941" EFFECT_SIZE="2.2427184466019416" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9258121009368341" LOG_CI_START="-0.22426259056289008" LOG_EFFECT_SIZE="0.3507747551869721" ORDER="546" O_E="0.0" SE="0.6755595667484758" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="0.4563807282253884" WEIGHT="6.668451771361085"/>
<DICH_DATA CI_END="3.748275808525094" CI_START="0.11857303655019144" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5738315399834706" LOG_CI_START="-0.9260140580948332" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="547" O_E="0.0" SE="0.8810167286666446" STUDY_ID="STD-Yasuda-2001" TOTAL_1="35" TOTAL_2="35" VAR="0.7761904761904761" WEIGHT="4.919045594493686"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Secondary adverse event outcomes</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other adverse effects</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5501169620020072" CI_END="2.497952781069008" CI_START="0.6147287429402372" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2391785073308126" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.3975842246245892" LOG_CI_START="-0.21131648004897832" LOG_EFFECT_SIZE="0.09313387228780544" METHOD="MH" NO="2" P_CHI2="0.8177284695280451" P_Q="0.0" P_Z="0.5487934231639788" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="493" TOTAL_2="506" WEIGHT="100.0" Z="0.5995691383629161">
<NAME>Total secondary adverse events</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.63057278598378" CI_START="0.4626278829153615" EFFECT_SIZE="1.1031664964249235" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.42005032290329436" LOG_CI_START="-0.3347681955356706" LOG_EFFECT_SIZE="0.04264106368381191" ORDER="548" O_E="0.0" SE="0.4433841341429744" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="0.1965894904097151" WEIGHT="68.70624389010946"/>
<DICH_DATA CI_END="4.92975532471565" CI_START="0.10349480816516624" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6928253647614487" LOG_CI_START="-0.9850814361179249" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="549" O_E="0.0" SE="0.9856107606091622" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="0.9714285714285713" WEIGHT="17.51198020680432"/>
<DICH_DATA CI_END="109.82496159254421" CI_START="0.2477702014744056" EFFECT_SIZE="5.216450216450217" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.040701060058013" LOG_CI_START="-0.6059509260205271" LOG_EFFECT_SIZE="0.7173750670187429" ORDER="550" O_E="0.0" SE="1.5546564777611582" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="2.4169567638447305" WEIGHT="3.425460563464862"/>
<DICH_DATA CI_END="16.85348707068295" CI_START="0.06464592714113662" EFFECT_SIZE="1.0437956204379562" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2266897722028904" LOG_CI_START="-1.1894588315855805" LOG_EFFECT_SIZE="0.01861547030865502" ORDER="551" O_E="0.0" SE="1.419257649993827" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="2.014292277066" WEIGHT="6.887099274172114"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="552" O_E="0.0" SE="0.0" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="75.99042388186619" CI_START="0.12186872490338482" EFFECT_SIZE="3.0431654676258995" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8807588670532034" LOG_CI_START="-0.914107732811309" LOG_EFFECT_SIZE="0.48332556712094726" ORDER="553" O_E="0.0" SE="1.6417184755732088" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="2.6952395530384203" WEIGHT="3.4692160654492463"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.463520127676112" CI_END="1.2281871564481195" CI_START="0.7495067928427023" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9594449523761268" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="113" I2="54.04339373347403" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.08926455151148514" LOG_CI_START="-0.12522442675068035" LOG_EFFECT_SIZE="-0.01797993761959761" METHOD="MH" NO="3" P_CHI2="0.006585045663444644" P_Q="0.0" P_Z="0.7424616361189962" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="878" TOTAL_2="890" WEIGHT="99.99999999999999" Z="0.32859525430360326">
<NAME>Total overall short-term complications</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.7437065088708765" CI_START="0.683010214468602" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6761178115702067" LOG_CI_START="-0.16557280136359445" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="554" O_E="0.0" SE="0.4944132324730442" STUDY_ID="STD-Arnold-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.24444444444444446" WEIGHT="4.466569606677191"/>
<DICH_DATA CI_END="1.2360248198903032" CI_START="0.40592721362637374" EFFECT_SIZE="0.7083333333333334" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" LOG_CI_END="0.09202719165342373" LOG_CI_START="-0.39155183232008783" LOG_EFFECT_SIZE="-0.14976232033333206" ORDER="555" O_E="0.0" SE="0.2840567124368153" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="0.08068821588041158" WEIGHT="21.439534112050517"/>
<DICH_DATA CI_END="1.7960865895519247" CI_START="0.2300920838262857" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.254327270225549" LOG_CI_START="-0.6380983227033753" LOG_EFFECT_SIZE="-0.1918855262389131" ORDER="556" O_E="0.0" SE="0.5242152108643809" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="0.2748015873015873" WEIGHT="5.885362305268769"/>
<DICH_DATA CI_END="27.20691780840997" CI_START="0.3168714508215705" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4346793446236137" LOG_CI_START="-0.49911688769257545" LOG_EFFECT_SIZE="0.46778122846551906" ORDER="557" O_E="0.0" SE="1.1359214793082617" STUDY_ID="STD-Chen-1998" TOTAL_1="47" TOTAL_2="46" VAR="1.2903176071538698" WEIGHT="0.9029194473713031"/>
<DICH_DATA CI_END="2.3370579861911978" CI_START="0.31436698699478227" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3686694880749161" LOG_CI_START="-0.5025630673361425" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="558" O_E="0.0" SE="0.511766315719159" STUDY_ID="STD-Cho-1998" TOTAL_1="42" TOTAL_2="42" VAR="0.26190476190476186" WEIGHT="6.253197449348067"/>
<DICH_DATA CI_END="16.53225360768315" CI_START="2.103751308787213" EFFECT_SIZE="5.897435897435898" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" LOG_CI_END="1.218332058814641" LOG_CI_START="0.32299439916754646" LOG_EFFECT_SIZE="0.7706632289910937" ORDER="559" O_E="0.0" SE="0.5259257732695968" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="0.27659791898922326" WEIGHT="3.5280246007171736"/>
<DICH_DATA CI_END="2.0966704832395915" CI_START="0.6411381374771846" EFFECT_SIZE="1.1594202898550725" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.3215301812733263" LOG_CI_START="-0.1930483887639497" LOG_EFFECT_SIZE="0.06424089625468829" ORDER="560" O_E="0.0" SE="0.3022659992448984" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="0.0913647342995169" WEIGHT="15.737530358845591"/>
<DICH_DATA CI_END="0.9463814519109611" CI_START="0.05189888608976906" EFFECT_SIZE="0.22162162162162163" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.023933780015435616" LOG_CI_START="-1.284841963351121" LOG_EFFECT_SIZE="-0.6543878716832783" ORDER="561" O_E="0.0" SE="0.7406637084875523" STUDY_ID="STD-Iwata-1998" TOTAL_1="37" TOTAL_2="41" VAR="0.5485827290705338" WEIGHT="8.47502951010544"/>
<DICH_DATA CI_END="0.544114458630633" CI_START="0.010126632491965794" EFFECT_SIZE="0.0742296918767507" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.26430973353157056" LOG_CI_START="-1.9945349508192003" LOG_EFFECT_SIZE="-1.1294223421753853" ORDER="562" O_E="0.0" SE="1.0163428573877098" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="53" VAR="1.0329528037630147" WEIGHT="12.26588730449044"/>
<DICH_DATA CI_END="6.41978801003991" CI_START="0.15576838338526122" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8075206873227565" LOG_CI_START="-0.8075206873227565" LOG_EFFECT_SIZE="0.0" ORDER="563" O_E="0.0" SE="0.9486832980505138" STUDY_ID="STD-Minami-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.8999999999999999" WEIGHT="1.7866278426708764"/>
<DICH_DATA CI_END="2.2823851969871054" CI_START="0.33544951176982485" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.35838894192641935" LOG_CI_START="-0.4743728358817928" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="564" O_E="0.0" SE="0.4891683905218266" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="0.23928571428571427" WEIGHT="7.1465113706835055"/>
<DICH_DATA CI_END="2.7021177779285344" CI_START="0.0075526549701142864" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4317042748080271" LOG_CI_START="-2.1219003548365407" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="565" O_E="0.0" SE="1.5" STUDY_ID="STD-Ochi-1999" TOTAL_1="55" TOTAL_2="55" VAR="2.25" WEIGHT="3.1265987246740337"/>
<DICH_DATA CI_END="2.827010570207606" CI_START="0.19897343360788772" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4513274323219404" LOG_CI_START="-0.7012049055385404" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="566" O_E="0.0" SE="0.67700320038633" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.45833333333333326" WEIGHT="3.5732556853417528"/>
<DICH_DATA CI_END="8.429699648808084" CI_START="0.5966744060020941" EFFECT_SIZE="2.2427184466019416" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9258121009368341" LOG_CI_START="-0.22426259056289008" LOG_EFFECT_SIZE="0.3507747551869721" ORDER="567" O_E="0.0" SE="0.6755595667484758" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="0.4563807282253884" WEIGHT="2.7330099177490137"/>
<DICH_DATA CI_END="3.748275808525094" CI_START="0.11857303655019144" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5738315399834706" LOG_CI_START="-0.9260140580948332" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="568" O_E="0.0" SE="0.8810167286666446" STUDY_ID="STD-Yasuda-2001" TOTAL_1="35" TOTAL_2="35" VAR="0.7761904761904761" WEIGHT="2.6799417640063146"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Other secondary outcomes</NAME>
<DICH_OUTCOME CHI2="0.17508189163862822" CI_END="5.783832614923851" CI_START="0.289480470933155" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2939499948478292" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.762215715913928" LOG_CI_START="-0.5383807295256573" LOG_EFFECT_SIZE="0.11191749319413531" METHOD="MH" NO="1" P_CHI2="0.6756346142570875" P_Q="0.0" P_Z="0.7358807162361349" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="154" WEIGHT="100.0" Z="0.33731332523575036">
<NAME>Long-term cholangitis</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.17508189163862822" CI_END="5.783832614923851" CI_START="0.289480470933155" DF="1.0" EFFECT_SIZE="1.2939499948478292" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.762215715913928" LOG_CI_START="-0.5383807295256573" LOG_EFFECT_SIZE="0.11191749319413531" NO="1" P_CHI2="0.6756346142570875" P_Z="0.7358807162361349" STUDIES="2" TAU2="0.0" TOTAL_1="158" TOTAL_2="154" WEIGHT="100.0" Z="0.33731332523575036">
<NAME>Cholangitis</NAME>
<DICH_DATA CI_END="6.848285213705944" CI_START="0.14602195568587464" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8355818393091744" LOG_CI_START="-0.8355818393091744" LOG_EFFECT_SIZE="0.0" ORDER="569" O_E="0.0" SE="0.9816498172140428" STUDY_ID="STD-Ochi-1999" TOTAL_1="55" TOTAL_2="55" VAR="0.9636363636363636" WEIGHT="60.568546170299"/>
<DICH_DATA CI_END="20.865360474038877" CI_START="0.17710468059086762" EFFECT_SIZE="1.9223300970873787" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3194258920687503" LOG_CI_START="-0.7517699609560325" LOG_EFFECT_SIZE="0.28382796555635886" ORDER="570" O_E="0.0" SE="1.2166306966515814" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="1.4801902520349122" WEIGHT="39.431453829701"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.203147381534853" CI_END="0.8060078963011945" CI_START="0.10210988691916896" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.28688216247663817" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-0.09366070347625181" LOG_CI_START="-0.9909322047636929" LOG_EFFECT_SIZE="-0.5422964541199724" METHOD="MH" NO="2" P_CHI2="0.5205540348649708" P_Q="0.0" P_Z="0.017829436764179907" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="382" TOTAL_2="382" WEIGHT="100.0" Z="2.3691413746984247">
<NAME>Long-term acute cholecystitis</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.203147381534853" CI_END="0.8060078963011945" CI_START="0.10210988691916896" DF="5.0" EFFECT_SIZE="0.28688216247663817" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-0.09366070347625181" LOG_CI_START="-0.9909322047636929" LOG_EFFECT_SIZE="-0.5422964541199724" NO="1" P_CHI2="0.5205540348649708" P_Z="0.017829436764179907" STUDIES="6" TAU2="0.0" TOTAL_1="382" TOTAL_2="382" WEIGHT="100.0" Z="2.3691413746984247">
<NAME>Acute cholecystitis</NAME>
<DICH_DATA CI_END="1.1121981112376143" CI_START="0.016213526060710883" EFFECT_SIZE="0.13428571428571429" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.046182153211859533" LOG_CI_START="-1.790122526040976" LOG_EFFECT_SIZE="-0.8719701864145581" ORDER="571" O_E="0.0" SE="1.0786544584478772" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="1.1634954407294833" WEIGHT="23.875818371402325"/>
<DICH_DATA CI_END="2.9373901930264825" CI_START="0.007323205191526685" EFFECT_SIZE="0.14666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4679616405720409" LOG_CI_START="-2.135298797038991" LOG_EFFECT_SIZE="-0.8336685782334751" ORDER="572" O_E="0.0" SE="1.5291680673997146" STUDY_ID="STD-Iwata-1998" TOTAL_1="37" TOTAL_2="41" VAR="2.338354978354978" WEIGHT="11.87989252100403"/>
<DICH_DATA CI_END="3.189856487989341" CI_START="0.03284261807485103" EFFECT_SIZE="0.32367149758454106" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5037711445379547" LOG_CI_START="-1.4835622300501372" LOG_EFFECT_SIZE="-0.4898955427560913" ORDER="573" O_E="0.0" SE="1.167369461691906" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="1.3627514600908501" WEIGHT="20.38479255561383"/>
<DICH_DATA CI_END="1.6402036392361539" CI_START="0.020908106769011874" EFFECT_SIZE="0.18518518518518517" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.21489777116126094" LOG_CI_START="-1.6796852908071978" LOG_EFFECT_SIZE="-0.7323937598229685" ORDER="574" O_E="0.0" SE="1.1128874689376813" STUDY_ID="STD-Ochi-1999" TOTAL_1="55" TOTAL_2="55" VAR="1.2385185185185186" WEIGHT="22.42954417188755"/>
<DICH_DATA CI_END="8.278832827562963" CI_START="0.011843604201898566" EFFECT_SIZE="0.31313131313131315" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9179691130796888" LOG_CI_START="-1.926516114606243" LOG_EFFECT_SIZE="-0.5042735007632773" ORDER="575" O_E="0.0" SE="1.6708647031716797" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="2.791788856304985" WEIGHT="9.950396411990377"/>
<DICH_DATA CI_END="103.38539765268268" CI_START="0.2323779323586732" EFFECT_SIZE="4.901477832512315" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.014459202522916" LOG_CI_START="-0.6338051168578909" LOG_EFFECT_SIZE="0.6903270428325126" ORDER="576" O_E="0.0" SE="1.555603570324088" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="2.41990246800505" WEIGHT="11.47955596810188"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.506001592950023" CI_END="0.905775922542785" CI_START="0.2092585366234308" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4353634620177045" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" I2="9.190000845584857" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-0.04297922797386781" LOG_CI_START="-0.6793168160929921" LOG_EFFECT_SIZE="-0.36114802203342994" METHOD="MH" NO="3" P_CHI2="0.3572883297042909" P_Q="0.0" P_Z="0.026099906352684478" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="382" TOTAL_2="382" WEIGHT="99.99999999999999" Z="2.224722001306299">
<NAME>Total long-term infections</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1401364009376709" CI_START="0.01789975589633139" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.05695681153903169" LOG_CI_START="-1.7471528915675454" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="577" O_E="0.0" SE="1.0597429700918628" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="1.123055162659123" WEIGHT="30.641543779051496"/>
<DICH_DATA CI_END="2.9585199623852754" CI_START="0.008426763462612409" EFFECT_SIZE="0.15789473684210525" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.47107450399143935" LOG_CI_START="-2.0743391964577724" LOG_EFFECT_SIZE="-0.8016323462331666" ORDER="578" O_E="0.0" SE="1.4951886076448944" STUDY_ID="STD-Iwata-1998" TOTAL_1="37" TOTAL_2="41" VAR="2.235588972431078" WEIGHT="14.554733295049461"/>
<DICH_DATA CI_END="3.1273299882361476" CI_START="0.03552906521827559" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4951737093557621" LOG_CI_START="-1.449416218795087" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="579" O_E="0.0" SE="1.1422617496711973" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="1.3047619047619048" WEIGHT="13.132090191022069"/>
<DICH_DATA CI_END="1.5722996913629688" CI_START="0.11681835873702631" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.19653532917174843" LOG_CI_START="-0.9324888997609374" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="580" O_E="0.0" SE="0.6631944208351271" STUDY_ID="STD-Ochi-1999" TOTAL_1="55" TOTAL_2="55" VAR="0.4398268398268398" WEIGHT="30.641543779051496"/>
<DICH_DATA CI_END="7.618637080220918" CI_START="0.014584119172649873" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8818772861059678" LOG_CI_START="-1.8361197955452926" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="581" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="6.5660450955110345"/>
<DICH_DATA CI_END="33.8033036625318" CI_START="0.4372771417917908" EFFECT_SIZE="3.8446601941747574" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5289591467952373" LOG_CI_START="-0.35924322435455713" LOG_EFFECT_SIZE="0.5848579612203401" ORDER="582" O_E="0.0" SE="1.1091394195658688" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="1.2301902520349122" WEIGHT="4.464043860314433"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3658330652184363" CI_END="1.0263733657514453" CI_START="0.5003280664478348" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7166054713299201" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.011305373630650286" LOG_CI_START="-0.3007451342112653" LOG_EFFECT_SIZE="-0.1447198802903075" METHOD="MH" NO="4" P_CHI2="0.8831706041191656" P_Q="0.0" P_Z="0.0690721251012661" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="433" TOTAL_2="435" WEIGHT="100.00000000000003" Z="1.8179477109496989">
<NAME>Total long-term complications</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3587581384605272" CI_START="0.4507618781988182" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.133142158366044" LOG_CI_START="-0.3460528201946176" LOG_EFFECT_SIZE="-0.10645533091428679" ORDER="583" O_E="0.0" SE="0.2814815024599325" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="0.07923183622710098" WEIGHT="42.40580094929107"/>
<DICH_DATA CI_END="2.9585199623852754" CI_START="0.008426763462612409" EFFECT_SIZE="0.15789473684210525" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.47107450399143935" LOG_CI_START="-2.0743391964577724" LOG_EFFECT_SIZE="-0.8016323462331666" ORDER="584" O_E="0.0" SE="1.4951886076448944" STUDY_ID="STD-Iwata-1998" TOTAL_1="37" TOTAL_2="41" VAR="2.235588972431078" WEIGHT="1.5029102027818564"/>
<DICH_DATA CI_END="3.3118971842772984" CI_START="0.1834243834156038" EFFECT_SIZE="0.7794117647058824" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5200768459286288" LOG_CI_START="-0.7365429321395233" LOG_EFFECT_SIZE="-0.10823304310544726" ORDER="585" O_E="0.0" SE="0.7381446780054547" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="53" VAR="0.5448575656677764" WEIGHT="6.166546429020213"/>
<DICH_DATA CI_END="3.1273299882361476" CI_START="0.03552906521827559" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4951737093557621" LOG_CI_START="-1.449416218795087" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="586" O_E="0.0" SE="1.1422617496711973" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="1.3047619047619048" WEIGHT="2.575097773494844"/>
<DICH_DATA CI_END="1.5722996913629688" CI_START="0.11681835873702631" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.19653532917174843" LOG_CI_START="-0.9324888997609374" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="587" O_E="0.0" SE="0.6631944208351271" STUDY_ID="STD-Ochi-1999" TOTAL_1="55" TOTAL_2="55" VAR="0.4398268398268398" WEIGHT="7.639118788694352"/>
<DICH_DATA CI_END="2.184067527945708" CI_START="0.3179592368637181" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.339266061945162" LOG_CI_START="-0.4976285540404116" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="588" O_E="0.0" SE="0.49159604012508756" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.2416666666666667" WEIGHT="13.902990934730783"/>
<DICH_DATA CI_END="1.559615454562759" CI_START="0.379104014785898" EFFECT_SIZE="0.7689320388349514" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.19301753005408087" LOG_CI_START="-0.4212416162854383" LOG_EFFECT_SIZE="-0.11411204311567873" ORDER="589" O_E="0.0" SE="0.36081886319164663" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="0.13019025203491222" WEIGHT="25.8075349219869"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Post hoc analysis</NAME>
<DICH_OUTCOME CHI2="9.910447713052045" CI_END="0.9809763481349724" CI_START="0.9387257106677714" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9596185281408843" ESTIMABLE="YES" EVENTS_1="733" EVENTS_2="776" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.008341463566328172" LOG_CI_START="-0.02746128712165302" LOG_EFFECT_SIZE="-0.017901375343990566" METHOD="MH" NO="1" P_CHI2="0.4483849672035005" P_Q="0.0" P_Z="2.4243389782766108E-4" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="806" TOTAL_2="814" WEIGHT="100.0" Z="3.6701228802065473">
<NAME>Overall success rate (w/repeated procedure)</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9447687113081946" CI_START="0.6283629123339872" EFFECT_SIZE="0.7704918032786885" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="-0.024674498048230756" LOG_CI_START="-0.20178945610186844" LOG_EFFECT_SIZE="-0.11323197707504959" ORDER="590" O_E="0.0" SE="0.10403820309388892" STUDY_ID="STD-Arnold-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.01082394770300528" WEIGHT="1.165352411050752"/>
<DICH_DATA CI_END="1.0719778093982864" CI_START="0.8927370702381119" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="92" LOG_CI_END="0.03018579528620809" LOG_CI_START="-0.049276431098668874" LOG_EFFECT_SIZE="-0.009545317906230389" ORDER="591" O_E="0.0" SE="0.04667650512284114" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="0.002178696130482615" WEIGHT="5.789569906653442"/>
<DICH_DATA CI_END="1.385755909370263" CI_START="0.7955946588753972" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.14168673925903227" LOG_CI_START="-0.09930814111915608" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="592" O_E="0.0" SE="0.14156158567804528" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="0.020039682539682552" WEIGHT="0.6294367951092436"/>
<DICH_DATA CI_END="1.0079836111769935" CI_START="0.8324005879290135" EFFECT_SIZE="0.915994623655914" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="46" LOG_CI_END="0.003453470965400657" LOG_CI_START="-0.0796676217157733" LOG_EFFECT_SIZE="-0.03810707537518634" ORDER="593" O_E="0.0" SE="0.04882574129696626" STUDY_ID="STD-Chen-1998" TOTAL_1="47" TOTAL_2="46" VAR="0.002383953013198277" WEIGHT="5.2910915118507615"/>
<DICH_DATA CI_END="1.0334585208774874" CI_START="0.831201712705974" EFFECT_SIZE="0.926829268292683" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="41" LOG_CI_END="0.01429305037257009" LOG_CI_START="-0.08029357057842075" LOG_EFFECT_SIZE="-0.03300026010292532" ORDER="594" O_E="0.0" SE="0.055560649357936934" STUDY_ID="STD-Cho-1998" TOTAL_1="42" TOTAL_2="42" VAR="0.003086985757075618" WEIGHT="4.086093861584172"/>
<DICH_DATA CI_END="1.0193935246409318" CI_START="0.8543694053610797" EFFECT_SIZE="0.9332409332409333" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="111" LOG_CI_END="0.00834187054988027" LOG_CI_START="-0.06835431195498358" LOG_EFFECT_SIZE="-0.03000622070255166" ORDER="595" O_E="0.0" SE="0.04505171725558338" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="0.002029657227677029" WEIGHT="6.214701369659853"/>
<DICH_DATA CI_END="1.0094978186992556" CI_START="0.9471067859718091" EFFECT_SIZE="0.9778048038917604" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="143" LOG_CI_END="0.004105384866681218" LOG_CI_START="-0.023601051679163314" LOG_EFFECT_SIZE="-0.009747833406241047" ORDER="596" O_E="0.0" SE="0.016274897976101876" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="2.648723041325249E-4" WEIGHT="47.621866673056786"/>
<DICH_DATA CI_END="1.017202411915782" CI_START="0.8712631866957009" EFFECT_SIZE="0.9414090582314881" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="53" LOG_CI_END="0.007407381272126959" LOG_CI_START="-0.0598506357337179" LOG_EFFECT_SIZE="-0.026221627230795446" ORDER="597" O_E="0.0" SE="0.03950769212178694" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="53" VAR="0.0015608577367899057" WEIGHT="8.081270480630792"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="598" O_E="0.0" SE="0.0" STUDY_ID="STD-Minami-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0111714878321025" CI_START="0.8776143514868973" EFFECT_SIZE="0.9420289855072463" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="69" LOG_CI_END="0.00482481523838741" LOG_CI_START="-0.05669628342718695" LOG_EFFECT_SIZE="-0.025935734094399757" ORDER="599" O_E="0.0" SE="0.03613779789050825" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="0.0013059404363752226" WEIGHT="9.658720414382115"/>
<DICH_DATA CI_END="1.0254487539365453" CI_START="0.8698389902155663" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="54" LOG_CI_END="0.010913961692508719" LOG_CI_START="-0.060561129142572986" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="600" O_E="0.0" SE="0.041984822163932733" STUDY_ID="STD-Ochi-1999" TOTAL_1="55" TOTAL_2="55" VAR="0.0017627252921370573" WEIGHT="7.155802216630188"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="601" O_E="0.0" SE="0.0" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1184366270979327" CI_START="0.9046335182125743" EFFECT_SIZE="1.0058703996387446" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="86" LOG_CI_END="0.04861138111803439" LOG_CI_START="-0.04352732494176465" LOG_EFFECT_SIZE="0.0025420280881348397" ORDER="602" O_E="0.0" SE="0.05412273203347673" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="0.0029292701227675282" WEIGHT="4.306094359391893"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6393053303897314" CI_END="1.3680200350270213" CI_START="0.8208479233079358" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0596869371637927" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.13609245779196644" LOG_CI_START="-0.08573729621297921" LOG_EFFECT_SIZE="0.025177580789493604" METHOD="MH" NO="2" P_CHI2="0.7553846552120591" P_Q="0.0" P_Z="0.6563847081093471" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="420" TOTAL_2="424" WEIGHT="100.00000000000001" Z="0.4449101229599239">
<NAME>Repeated same procedure</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="34.31066610907661" CI_START="0.4663272916105621" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5354291495539343" LOG_CI_START="-0.3313091668980096" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="603" O_E="0.0" SE="1.0965313275875672" STUDY_ID="STD-Cho-1998" TOTAL_1="42" TOTAL_2="42" VAR="1.2023809523809526" WEIGHT="1.4121236010142404"/>
<DICH_DATA CI_END="1.5412908167915613" CI_START="0.615397565419584" EFFECT_SIZE="0.9739130434782609" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="30" LOG_CI_END="0.1878845908350117" LOG_CI_START="-0.2108442262018718" LOG_EFFECT_SIZE="-0.011479817683430055" ORDER="604" O_E="0.0" SE="0.23421528086694174" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="0.05485679779158041" WEIGHT="30.951688553131756"/>
<DICH_DATA CI_END="3.3636234107148737" CI_START="0.43701626379373393" EFFECT_SIZE="1.2124183006535947" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5268073664945876" LOG_CI_START="-0.3595024002276559" LOG_EFFECT_SIZE="0.08365248313346585" ORDER="605" O_E="0.0" SE="0.5206227442767486" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="53" VAR="0.27104804185825276" WEIGHT="6.264241972111577"/>
<DICH_DATA CI_END="1.9633266682913513" CI_START="0.7334490094066755" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="20" LOG_CI_END="0.29299256574017213" LOG_CI_START="-0.13463007364492244" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="606" O_E="0.0" SE="0.25118765514100827" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="0.0630952380952381" WEIGHT="26.910279943856285"/>
<DICH_DATA CI_END="1.7830836823835672" CI_START="0.28613580320057064" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.251171725645683" LOG_CI_START="-0.5434277970021589" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="607" O_E="0.0" SE="0.4667516929344155" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.21785714285714286" WEIGHT="7.793687634013022"/>
<DICH_DATA CI_END="1.7131310879769877" CI_START="0.6371323972013421" EFFECT_SIZE="1.044744617982271" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="23" LOG_CI_END="0.2337905962444572" LOG_CI_START="-0.1957703111508123" LOG_EFFECT_SIZE="0.019010142546822453" ORDER="608" O_E="0.0" SE="0.2523262033647664" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="0.06366851290447746" WEIGHT="26.667978295873123"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8022685180501785" CI_END="20.996743098794305" CI_START="3.276387929476557" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.294183241718851" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="1.3221519345473807" LOG_CI_START="0.5153953172815289" LOG_EFFECT_SIZE="0.9187736259144548" METHOD="MH" NO="3" P_CHI2="0.9699697229801758" P_Q="0.0" P_Z="8.036681950012969E-6" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="619" TOTAL_2="627" WEIGHT="99.99999999999999" Z="4.464204391258684">
<NAME>Switched to different procedure</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="251.4242022543601" CI_START="0.8949019147025976" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.400407080826505" LOG_CI_START="-0.04822456271514261" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="609" O_E="0.0" SE="1.438338348338483" STUDY_ID="STD-Arnold-2001" TOTAL_1="30" TOTAL_2="30" VAR="2.0688172043010753" WEIGHT="10.855208199374584"/>
<DICH_DATA CI_END="322.13779473233694" CI_START="1.120638453181048" EFFECT_SIZE="19.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.508041681295241" LOG_CI_START="0.04946552061041675" LOG_EFFECT_SIZE="1.2787536009528289" ORDER="610" O_E="0.0" SE="1.4441798069345388" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="2.085655314757482" WEIGHT="10.767570902168734"/>
<DICH_DATA CI_END="140.7767178324238" CI_START="0.4347850511020366" EFFECT_SIZE="7.823529411764706" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1485308355377537" LOG_CI_START="-0.36172539636013007" LOG_EFFECT_SIZE="0.8934027195888119" ORDER="611" O_E="0.0" SE="1.4745369365855683" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="2.1742591773551525" WEIGHT="10.328778515933083"/>
<DICH_DATA CI_END="129.10439400348557" CI_START="0.3638884722480947" EFFECT_SIZE="6.854166666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1109410235134614" LOG_CI_START="-0.4390317023646873" LOG_EFFECT_SIZE="0.835954660574387" ORDER="612" O_E="0.0" SE="1.4978666017493918" STUDY_ID="STD-Chen-1998" TOTAL_1="47" TOTAL_2="46" VAR="2.243604356636271" WEIGHT="10.009537293288915"/>
<DICH_DATA CI_END="395.69566244713593" CI_START="1.4057273947653333" EFFECT_SIZE="23.584745762711865" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.597361289625142" LOG_CI_START="0.14790110843069337" LOG_EFFECT_SIZE="1.3726311990279176" ORDER="613" O_E="0.0" SE="1.4388250354570657" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="2.0702174826580264" WEIGHT="10.84786582436852"/>
<DICH_DATA CI_END="36.880621398214366" CI_START="0.47237680478348576" EFFECT_SIZE="4.173913043478261" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5667982298312133" LOG_CI_START="-0.32571143578726236" LOG_EFFECT_SIZE="0.6205433970219755" ORDER="614" O_E="0.0" SE="1.1116695456582237" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="1.2358091787439613" WEIGHT="18.172256579257077"/>
<DICH_DATA CI_END="137.31350138495023" CI_START="0.3848253481512557" EFFECT_SIZE="7.269230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1377132414516398" LOG_CI_START="-0.4147363290467869" LOG_EFFECT_SIZE="0.8614884562024261" ORDER="615" O_E="0.0" SE="1.4993215125399215" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="53" VAR="2.247964997964998" WEIGHT="9.990120619967906"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="616" O_E="0.0" SE="0.0" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="40.40955456380315" CI_START="0.5715469153980235" EFFECT_SIZE="4.805825242718447" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6064840632229367" LOG_CI_START="-0.24294811476614378" LOG_EFFECT_SIZE="0.6817679742283965" ORDER="617" O_E="0.0" SE="1.0863656161877142" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="1.1801902520349121" WEIGHT="19.02866206564118"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.939497443482189" CI_END="1.6630432270494397" CI_START="1.0847284628303684" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3431121782255546" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="121" I2="7.260694996739826" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.2209035378695819" LOG_CI_START="0.03532103601555482" LOG_EFFECT_SIZE="0.12811228694256832" METHOD="MH" NO="4" P_CHI2="0.37345368037598137" P_Q="0.0" P_Z="0.006809386735284457" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.011306347860188457" TOTALS="YES" TOTAL_1="828" TOTAL_2="907" WEIGHT="99.99999999999999" Z="2.7060252542774568">
<NAME>Stone removal requiring mechanical lithotripsy</NAME>
<GROUP_LABEL_1>EBD</GROUP_LABEL_1>
<GROUP_LABEL_2>ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EBD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ES</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.284464171776895" CI_START="1.3272115962603706" EFFECT_SIZE="2.3846153846153846" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="13" LOG_CI_END="0.631896515456072" LOG_CI_START="0.1229401675987999" LOG_EFFECT_SIZE="0.3774183415274359" ORDER="618" O_E="0.0" SE="0.2989634781059154" STUDY_ID="STD-Bergman-1997a" TOTAL_1="101" TOTAL_2="101" VAR="0.08937916124118617" WEIGHT="11.802724884361307"/>
<DICH_DATA CI_END="3.2123968775739593" CI_START="0.2216146041822971" EFFECT_SIZE="0.84375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5068291951037336" LOG_CI_START="-0.6544016234255708" LOG_EFFECT_SIZE="-0.07378621416091866" ORDER="619" O_E="0.0" SE="0.6821127309893708" STUDY_ID="STD-Bergman-2001a" TOTAL_1="16" TOTAL_2="18" VAR="0.4652777777777777" WEIGHT="2.4935017761546536"/>
<DICH_DATA CI_END="70.30165551536152" CI_START="0.12274115291800639" EFFECT_SIZE="2.9375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469655522277983" LOG_CI_START="-0.9110098016682132" LOG_EFFECT_SIZE="0.4679778752797927" ORDER="620" O_E="0.0" SE="1.6200483750766987" STUDY_ID="STD-Chen-1998" TOTAL_1="47" TOTAL_2="46" VAR="2.624556737588652" WEIGHT="0.45084411642079814"/>
<DICH_DATA CI_END="3.1694826926349604" CI_START="0.9413116788152727" EFFECT_SIZE="1.7272727272727273" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.5009883845939844" LOG_CI_START="-0.026266553004776545" LOG_EFFECT_SIZE="0.23736091579460392" ORDER="621" O_E="0.0" SE="0.30971216029954607" STUDY_ID="STD-Cho-1998" TOTAL_1="42" TOTAL_2="42" VAR="0.09592162223741171" WEIGHT="11.082587525285788"/>
<DICH_DATA CI_END="22.317603752132403" CI_START="0.18853986748061408" EFFECT_SIZE="2.051282051282051" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.34864756243879" LOG_CI_START="-0.7245968025079015" LOG_EFFECT_SIZE="0.3120253799654443" ORDER="622" O_E="0.0" SE="1.2178340026948082" STUDY_ID="STD-DiSario-2004" TOTAL_1="117" TOTAL_2="120" VAR="1.4831196581196582" WEIGHT="0.7951971921060152"/>
<DICH_DATA CI_END="2.243441536350994" CI_START="0.6717600980578469" EFFECT_SIZE="1.227621483375959" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.35091475638703945" LOG_CI_START="-0.17278579642759856" LOG_EFFECT_SIZE="0.08906447997972042" ORDER="623" O_E="0.0" SE="0.3076242970828638" STUDY_ID="STD-Fujita-2003" TOTAL_1="138" TOTAL_2="144" VAR="0.09463270815572605" WEIGHT="11.217424512323966"/>
<DICH_DATA CI_END="1.7113690810452193" CI_START="0.6399903365202627" EFFECT_SIZE="1.0465465465465464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.23334368141467055" LOG_CI_START="-0.19382658355925392" LOG_EFFECT_SIZE="0.019758548927708314" ORDER="624" O_E="0.0" SE="0.2509219281725975" STUDY_ID="STD-Iwata-1998" TOTAL_1="37" TOTAL_2="41" VAR="0.0629618140378542" WEIGHT="16.000979873405225"/>
<DICH_DATA CI_END="12.686170783310939" CI_START="0.10910171939380674" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="1.1033305536443154" LOG_CI_START="-0.9621684050729006" LOG_EFFECT_SIZE="0.07058107428570727" ORDER="625" O_E="0.0" SE="1.213284312735235" STUDY_ID="STD-Lin-2004" TOTAL_1="51" TOTAL_2="120" VAR="1.4720588235294119" WEIGHT="0.8011266454720217"/>
<DICH_DATA CI_END="1.6122676419231254" CI_START="0.7155357377401774" EFFECT_SIZE="1.0740740740740742" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="27" LOG_CI_END="0.20743713781774945" LOG_CI_START="-0.14536867033781184" LOG_EFFECT_SIZE="0.031034233739968817" ORDER="626" O_E="0.0" SE="0.20723987812749292" STUDY_ID="STD-Natsui-2002" TOTAL_1="70" TOTAL_2="70" VAR="0.04294836708629812" WEIGHT="21.90341180370236"/>
<DICH_DATA CI_END="16.105127556014633" CI_START="0.7606273193052175" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.206964168873432" LOG_CI_START="-0.11882808017288078" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="627" O_E="0.0" SE="0.7787769298672801" STUDY_ID="STD-Ochi-1999" TOTAL_1="55" TOTAL_2="55" VAR="0.6064935064935064" WEIGHT="1.923541022858569"/>
<DICH_DATA CI_END="2.9678388218115828" CI_START="0.5990142607180446" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.4724403114659669" LOG_CI_START="-0.2225628382493669" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="628" O_E="0.0" SE="0.40824829046386296" STUDY_ID="STD-Tanaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.16666666666666663" WEIGHT="6.677210963272548"/>
<DICH_DATA CI_END="1.5143639538977969" CI_START="0.24704518050119664" EFFECT_SIZE="0.6116504854368932" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.1802302636541084" LOG_CI_START="-0.6072236141572894" LOG_EFFECT_SIZE="-0.21349667525159052" ORDER="629" O_E="0.0" SE="0.4625543057859758" STUDY_ID="STD-Vlavianos-2003" TOTAL_1="103" TOTAL_2="99" VAR="0.21395648580114598" WEIGHT="5.27545243238836"/>
<DICH_DATA CI_END="3.648195405162013" CI_START="0.9779907154971744" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.5620780920222845" LOG_CI_START="-0.009665268144386372" LOG_EFFECT_SIZE="0.27620641193894907" ORDER="630" O_E="0.0" SE="0.33584487993717976" STUDY_ID="STD-Yasuda-2001" TOTAL_1="35" TOTAL_2="35" VAR="0.11279178338001868" WEIGHT="9.57599725224837"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-10-16 17:59:49 +0100" MODIFIED_BY="dimitrinka nikolova">
<APPENDIX ID="APP-01" MODIFIED="2008-10-16 17:59:49 +0100" MODIFIED_BY="dimitrinka nikolova" NO="1">
<TITLE MODIFIED="2008-10-16 17:59:21 +0100" MODIFIED_BY="dimitrinka nikolova">Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-16 17:59:49 +0100" MODIFIED_BY="dimitrinka nikolova">
<TABLE COLS="3" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Time of search</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Searched items</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>January 2004.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(sphinctero* OR ((balloon OR papillary) AND dilation)) AND ('bile duct stone*' OR cholelithiasis OR calculi)<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials in The Cochrane Library (CENTRAL)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 4, 2003.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1. SPHINCTEROTOMY TRANSHEPATIC explode all trees (MeSH)<BR/>#2. SPHINCTEROTOMY ENDOSCOPIC explode all trees(MeSH)<BR/>#3. BALLOON DILATATION explode all trees (MeSH)<BR/>#4. sphinctero*<BR/>#5. ((balloon or papillary) and dilat*)<BR/>#6. (#1 or #2 or #3 or #4 or #5)<BR/>#7. COMMON BILE DUCT CALCULI explode all trees (MeSH)<BR/>#8. CHOLELITHIASIS explode all trees (MeSH)<BR/>#9. ((common next bile next duct next stone*) or (bile next duct nextstone*) or cholelithiasis or calculi)<BR/>#10. (#7 or #8 or #9)<BR/>#11. (#6 and #10)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>January 1966 to January 2004.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.endoscopic sphincteroplasty OR endoscopic sphincteroclasy OR (endoscopic AND (balloon OR papillary) AND (sphincteroplasty OR sphincteroclasy OR (dilation OR dilatation) AND (bile OR cholelithiasis OR stones))) AND clinical trial<BR/>
<BR/>The details of the search are as follows:<BR/>((((endoscopic[All Fields] AND sphincteroplasty[All Fields]) OR (endoscopic[All Fields] AND sphincteroclasy[All Fields])) OR ((endoscopic[All Fields] AND (("balloon dilatation"[MeSH Terms] OR balloon[Text Word]) OR papillary[All Fields])) AND (((sphincteroplasty[All Fields] OR sphincteroclasy[All Fields]) OR (("dilatation, pathologic"[MeSH Terms] OR dilation[Text Word]) OR (("dilatation, pathologic"[MeSH Terms] OR "dilatation"[MeSH Terms]) OR dilatation[Text Word]))) AND ((("bile"[MeSH Terms] OR bile[Text Word]) OR ("cholelithiasis"[MeSH Terms] OR cholelithiasis[Text Word])) OR stones[All Fields])))) AND (("clinical trial"[Publication Type] OR "clinical trials"[MeSH Terms]) OR "clinical trial"[Text Word]))<BR/>
<BR/>2.endoscopic sphincteroplasty OR endoscopic sphincteroclasy OR (endoscopic AND (balloon OR papillary) AND (sphincteroplasty OR sphincteroclasy OR (dilation OR dilatation) AND (bile OR cholelithiasis OR stones))) AND LIMIT TO 90 days<BR/>
<BR/>The details of the search are as follows:<BR/>((((endoscopic[All Fields] AND sphincteroplasty[All Fields]) OR (endoscopic[All Fields] AND sphincteroclasy[All Fields])) OR ((endoscopic[All Fields] AND (("balloon dilatation"[MeSH Terms] OR balloon[Text Word]) OR papillary[All Fields])) AND (((sphincteroplasty[All Fields] OR sphincteroclasy[All Fields]) OR (("dilatation, pathologic"[MeSH Terms] OR dilation[Text Word]) OR (("dilatation, pathologic"[MeSH Terms] OR "dilatation"[MeSH Terms]) OR dilatation[Text Word]))) AND ((("bile"[MeSH Terms] OR bile[Text Word]) OR ("cholelithiasis"[MeSH Terms] OR cholelithiasis[Text Word])) OR stones[All Fields])))) AND ((LIMIT[All Fields] AND 90[All Fields]) AND days[All Fields]))<BR/>
<BR/>The reason for search number 2 is that it allows a search of articles recently archived but not yet categorized under their MESH headings.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>January 1980 to January 2004.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SilverPlatterASCII 3.0WINNSelected Databases<BR/>1. explode "sphincteroplasty"/ all subheadings<BR/>2. explode "sphincterotomy"/ all subheadings<BR/>3. explode "endoscopic-sphincterotomy"/ all subheadings<BR/>4. explode "balloon-dilatation"/ all subheadings<BR/>5. explode "bile-duct-dilatation"/ all subheadings<BR/>6. sphinctero*<BR/>7. (balloon or papillary) and dilat*<BR/>8. explode "common-bile-duct-stone"/ all subheadings<BR/>9. explode "bile-duct-stone"/ all subheadings<BR/>10. explode "cholelithiasis"/ all subheadings<BR/>11. explode "stone-formation"/ all subheadings<BR/>12. common bile duct stone* or bile duct stone* or cholelithiasis or calculi<BR/>13. #1 or #2 or #3 or #4 or #5 or #6 or #7<BR/>14. #8 or #9 or #10 or #11 or #12<BR/>15. #13 and #14<BR/>16. random* or blind* or placebo* or meta-analysis<BR/>17. #15 and #16<BR/>
<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>